Contents

03 Letters from Leaders
07 2023 by the Numbers
08 Highlights
32 Patient Perspectives
36 Department
38 Happenings
43 Faculty
56 Residents & Fellows
58 Education
68 Grants & Clinical Trials
80 Giving

08 Viterbi Breaking Ground
12 Visionary Transformation Winning Faculty
16 Award Winning Faculty
32 Blind Infant Receives Gift of Sight

On the Cover | Retinal Degeneration: Immunocytochemistry on CRISPR-Cas9 edited hTERT-RPE1 cells. Cells were stained with vimentin (red) and acetylated α-tubulin (green) for visualization of cytoskeleton and cilia structure. This experiment was carried out in order to observe the effects of a putative disease-causing mutation on cilia and overall cell structure. Image Credit | Radha Ayyagari, PhD and lab

Letter from the Chair

Dear Friends,

Over the past year, the Shiley Eye Institute (SEI) and Viterbi Family Department of Ophthalmology reaffirmed its dedication to improving the vision and lives of patients. Each day, our dedicated team of staff, clinicians, researchers, and trainees demonstrates their passion for caring for patients, discovering, learning, and community service. We are privileged to have a team of unique individuals contributing to our environment of excellence and innovation.

The Viterbi Family Vision Research Center broke ground, beginning the process of constructing our future 5-story 100,000-square-foot facility. This state-of-the-art center, encompassing laboratories, clinical trial operations, and educational space will further enhance our capabilities.

The Hanna and Mark Gleiberman Center for Glaucoma Research will be housed within the Viterbi Family Vision Research Center. This generous gift will allow SEI to intensively research on advanced glaucoma, with the objective of protecting and restoring the vision of those affected by the disease.

The visionary transformation and renovation of the Shiley Eye Center, supported by Darlene Shiley, began with the gutting of the second floor. Upon completion, this will provide additional clinical areas, dedicated ophthalmic procedure rooms, a laser center, and a specialized microsurgery training center.

You can read more about our notable accomplishments including new faculty, a new adult eyemobile, prestigious grant awards, personalized medicine with the addition of a genetic counselor as well as initiatives to advance diversity and inclusion at SEI.

Thanks to the engagement and support of our entire SEI team, we have celebrated a year filled with accomplishments and success. Together, we have taken groundbreaking steps towards creating a brighter future for our patients. Your continued support and partnership have been instrumental in our journey, and there is no limit to what we can achieve.

Sincerely,

Robert N. Weinreb, MD
Chair and Distinguished Professor, Ophthalmology
Director, Shiley Eye Institute
Dear Friends,

We are pleased to share this report highlighting another remarkable year of excellence in education, clinical care, community service and collaborative research for the Shiley Eye Institute and Viterbi Family Department of Ophthalmology. Inside, you will find inspiring stories of groundbreaking research, innovative treatments and cures and patient experiences that demonstrate the transformative impact of this world-renowned center for ophthalmological research and care.

Our successes in research and clinical care will soon be enhanced with brand new, modern facilities complete with state-of-the-art equipment. Construction continues on new exam rooms and a laser center at the Shiley Eye Institute with completion estimated by early 2025. The Viterbi Family Vision Research Center is also well underway as an education center, space for clinical trials and wet and dry research labs are expected to be complete early 2026. These upgrades will allow us to develop new programs, expand existing programs and provide new spaces for many patients with unmet vision care needs as part of our commitment to serve our community.

Today, that vision has only become bigger and bolder. The Shiley Eye Institute embraces both a personal and world view: a combination of superb, personalized patient care with a focus on addressing the great challenges to human health and sight, from glaucoma and diabetic retinopathy to the simple need for a good set of glasses.

Its members are driven by compassion and sustained by incomparable basic and translational research that sees beyond the ways or obvious, bringing together the world-class faculty in the Viterbi Family Department of Ophthalmology with their esteemed collaborators across campus at Halıcıoğlu Data Science Institute, Moores Cancer Center and from more than a dozen academic departments at UC San Diego.

Its impact goes well beyond the San Diego region to multidisciplinary academic and clinical projects across the nation and around the world, made possible by highly competitive grants from the National Eye Institute, private foundations and, particularly, transformative gifts from some of our most generous philanthropic partners.

Shiley’s distinguished reputation is a testament to the faculty, staff and friends who have worked to make its early vision a reality. The expansion of Shiley Eye Institute’s clinical services and the imminent opening of Viterbi Family Vision Research Center signal an even brighter future, one that I expect will continue to benefit our community and beyond for many years to come.

John M. Carethers, MD

Vice Chancellor for Health Sciences
UC San Diego
Executive Committee

ROBERT N. WEINREB, MD
CHAIR

NATALIE A. AFSHARI, MD
VICE CHAIR, EDUCATION

DON O. KIKKAWA, MD
EXECUTIVE VICE CHAIR, CLINICAL

WILLIAM FREEMAN, MD
VICE CHAIR

DAVID B. GRANET, MD
VICE CHAIR, PEDIATRIC OPHTHALMOLOGY

SALLY BAXTER, MD, MSc
DIVISION CHIEF, INFORMATICS AND DATA SCIENCE

LINDA ZANGWILL, PhD
INTERIM DIRECTOR, RESEARCH

CRAIG KISHABA, MBA
ADMINISTRATIVE VICE CHAIR

2023 Year in Review

173,933
CLINICAL VISITS

7,718
SURGERIES

102,228
PATIENT CALLS

263,163
EYEMOBILE FOR CHILDREN
Total Children Screened Since 1999

7,132
TRIAGE/ SAME DAY APPTS
Supported by a $50 million gift made in 2018 by philanthropist Andrew J. Viterbi, PhD, the future 5-story, 100,000-square-foot facility will house laboratories, clinical trials operations, as well as administrative and educational spaces to support a variety of research efforts, including curing glaucoma blindness, restoring vision of patients blinded by macular degeneration and providing sight to individuals who have reversible vision loss due to cataracts or infections.

"UC San Diego's growth and expansion has been made possible by many people who believe in our ability to make a positive impact in the community and the world," said Chancellor Pradeep Khosla. "We are grateful to Dr. Andrew Viterbi for his transformational generosity. The Viterbi Family Vision Research Center will be a hub for interdisciplinary ophthalmology. With this investment, our leading-edge researchers will be empowered to conduct groundbreaking research with the goal of finding new treatments and cures for vision loss and eye disease."

Robert N. Weinreb, MD, Chair and Distinguished Professor of Ophthalmology, director of the Shiley Eye Institute and holder of the Morris Gleck, MD, Chair in Glaucoma illustrated the real-world impact of the new center, introducing a patient in attendance who had flown in from India for continuing eye care. Weinreb shared that the patient had come to Shiley Eye Institute since he was a baby. "He could have gone anywhere in the world, but he came to UC San Diego," said Weinreb. "Today, he travels throughout the world making a difference as a diplomat for India."

Weinreb continued, "In this new building, there will be clinical trials for gene therapy, stem cell therapy and more. We are building bridges with other departments across the university, including neuroscience, data science, bioinformatics, engineering, stem cell biology and gene therapy. Our dream is the realization of the impossible. We are going to cure blinding eye diseases."

Robert N. Weinreb, MD, Tom Cermuly, Andrew Viterbi, PhD, Pradeep Khosla, PhD, Betty Hayward, MPH, MBA, and John M. Canellakis, MD

Supporters, patients, friends and campus leadership came together on March 24, 2023 to celebrate the groundbreaking of the new Viterbi Family Vision Research Center at the Shiley Eye Institute where research will focus on treating and curing eye diseases and conditions causing vision loss.

Viterbi's generous gift was inspired by his late father, Achille Viterbi, a celebrated ophthalmologist. The donation established the new center which is now under construction, as well as the Viterbi Family Department of Ophthalmology and six new endowed chairs to recruit top faculty to UC San Diego. In attendance at the event were the holders of the first three endowed chairs that have been filled: Radha Ayyagari, PhD, Eric Nudleman, MD, PhD, and Alex Huang, MD, PhD.

"I believe that the best way to contribute to society is to promote the people who are most able to make an impact," said Viterbi. "As part of my giving, I have emphasized the creation of endowed chairs, and I am proud that three researchers who hold the chairs I established are here today. These researchers need space to do their work, so this is going to be a tremendous facility that will serve that purpose. I believe it will be one of the best places in the U.S. – and in the world – for ophthalmology."

Vice Chancellor for Health Sciences John M. Carethers, MD thanked Viterbi and pointed out that the event attendees were sitting where the UC San Diego's newest research facility would soon be constructed. "Buildings are important to the positive impact in the community and the world," said Chancellor Pradeep Khosla. "We are grateful to Dr. Andrew Viterbi for his transformational generosity. The Viterbi Family Vision Research Center will be a hub for interdisciplinary ophthalmology. With this investment, our leading-edge researchers will be empowered to conduct groundbreaking research with the goal of finding new treatments and cures for vision loss and eye disease."

Robert N. Weinreb, MD, Chair and Distinguished Professor of Ophthalmology, director of the Shiley Eye Institute and holder of the Morris Gleck, MD, Chair in Glaucoma illustrated the real-world impact of the new center, introducing a patient in attendance who had flown in from India for continuing eye care. Weinreb shared that the patient had come to Shiley Eye Institute since he was a baby. "He could have gone anywhere in the world, but he came to UC San Diego," said Weinreb. "Today, he travels throughout the world making a difference as a diplomat for India."

Weinreb continued, "In this new building, there will be clinical trials for gene therapy, stem cell therapy and more. We are building bridges with other departments across the university, including neuroscience, data science, bioinformatics, engineering, stem cell biology and gene therapy. Our dream is the realization of the impossible. We are going to cure blinding eye diseases."

Viterbi Family Vision Research Center
Breaks Ground

"I believe that the best way to contribute to society is to promote the people who are most able to make an impact," said Viterbi. "As part of my giving, I have emphasized the creation of endowed chairs, and I am proud that three researchers who hold the chairs I established are here today. These researchers need space to do their work, so this is going to be a tremendous facility that will serve that purpose. I believe it will be one of the best places in the U.S. – and in the world – for ophthalmology."

Vice Chancellor for Health Sciences John M. Carethers, MD thanked Viterbi and pointed out that the event attendees were sitting where the UC San Diego's newest research facility would soon be constructed. "Buildings are important to the

Viterbi's generous gift was inspired by his late father, Achille Viterbi, a celebrated ophthalmologist. The donation established the new center which is now under construction, as well as the Viterbi Family Department of Ophthalmology and six new endowed chairs to recruit top faculty to UC San Diego. In attendance at the event were the holders of the first three endowed chairs that have been filled: Radha Ayyagari, PhD, Eric Nudleman, MD, PhD, and Alex Huang, MD, PhD.

"I believe that the best way to contribute to society is to promote the people who are most able to make an impact," said Viterbi. "As part of my giving, I have emphasized the creation of endowed chairs, and I am proud that three researchers who hold the chairs I established are here today. These researchers need space to do their work, so this is going to be a tremendous facility that will serve that purpose. I believe it will be one of the best places in the U.S. – and in the world – for ophthalmology."

Vice Chancellor for Health Sciences John M. Carethers, MD thanked Viterbi and pointed out that the event attendees were sitting where the UC San Diego's newest research facility would soon be constructed. "Buildings are important to the
“The Viterbi Family Vision Research Center, named in recognition of Dr. Viterbi’s generosity, will support the world’s foremost researchers as they pursue tomorrow’s treatments and cures for blinding eye diseases,” says Dr. Weinreb.

Currently, researchers within the Department of Ophthalmology are spread across different buildings in the School of Medicine and general campus. The new building will establish a shared home in a facility that, by its very design, encourages collaboration and crosscutting interdisciplinary projects. It will also house educational space where researchers, students and clinicians can come together to share ideas and inspire new ones.

grow our research impact, but we have to fill them with talented people, and I’d like to thank Dr. Viterbi for his support of six endowed chairs as part of his gift,” said Carethers. “Bringing excellent researchers to campus is critical to furthering our tripartite mission, as it also strengthens our patient care and plays a key role in providing education to new generations of health professionals.”

The facility will also be home to the newly established Hanna and Mark Gleiberman Center for Glaucoma Research, which was funded by a $20 million gift in 2022 from the Gleibermans.

Thanks to support from the Nixon Visions Foundation, led by UC San Diego alumnus Brandon Nixon ’83, and his wife, Janine, research on inherited retinal degenerations, retinal conditions that can result in vision loss, and for which there currently is no cure, also will take place in the center.
On December 4, 2023, distinguished guests, faculty, and staff celebrated progress on the second-floor renovation and the clinical expansion of the Donald P. and Darlene V. Shiley Eye Institute (SEI). Benefactor Darlene Shiley, Vice Chancellor of UC San Diego Health Sciences John M. Carey, MD, CEO of UC San Diego Health Patty Maysent and Robert N. Weinreb, MD, Director of the Shiley Eye Institute and Chair of the Viterbi Family Department of Ophthalmology were in attendance, and each signed the main structural beam. This SEI transformation was made possible through the extraordinary generosity of Mrs. Shiley, who made a $10 million donation in partnership with UC San Diego Health. This endeavor represents her profound commitment to ensuring that SEI remains at the forefront of innovation, delivering exceptional care, and shaping the future of eye health for generations to come.

Mrs. Shiley's donation to support the expansion of the Shiley Eye Institute at UC San Diego Health carries with it a profound legacy. She and her late husband, Donald, who passed away in 2010, have contributed to funding for SEI clinical enhancements, state-of-the-art equipment, groundbreaking research initiatives, and an endowed chair. Their commitment to SEI and the field of eye health has been a driving force behind its evolution.

The current transformative journey of SEI's expansion commenced this past July 2023 with the demolition work on the second floor. The completion of this expansive project is on track, with a slated finish date set for late 2024, marking the dawn of a new era for SEI and the communities it serves. The upcoming renovation aims to expand patient capacity and comfort to serve the growing demand in the San Diego community and beyond.

The renovation and expansion of SEI promises a host of remarkable enhancements. There will be additional clinical areas, dedicated ophthalmic procedure rooms equipped with cutting-edge technology, a laser center, and the creation of a highly specialized microsurgery training center designed to support residents and fellows.

Patients, clinicians, staff and trainees at the Donald P. and Darlene V. Shiley Eye Institute and Viterbi Family Department of Ophthalmology are grateful for Mrs. Shiley’s longstanding unwavering support!

A Visionary Transformation
Chancellor Pradeep Khosla and Thespine Kavoulakis hosted an intimate celebration at the Audrey Geisel University House on March 23, 2023, to thank Hanna and Mark Gleiberman for their generous gift establishing the Hanna and Mark Gleiberman Center for Glaucoma Research at the Shiley Eye Institute (SEI) and Viterbi Family Department of Ophthalmology.

The trailblazing donation will expand SEI’s research on advanced glaucoma with the ultimate goal of protecting and restoring the vision of those who suffer with the disease. In addition to establishing the center, their gift will create three new endowed chairs to support the recruitment of exceptional vision scientists to the research teams.

In his toast to the couple, Robert N. Weinreb, MD stated, “We are so grateful to Hanna and Mark Gleiberman for making this generous investment to accelerate laboratory discoveries in glaucoma.”

The new Gleiberman Center for Glaucoma Research will be located in the Viterbi Family Vision Research Center which will be completed in 2025.

**Accolades**

Natalie A. Afshari, MD, Professor of Ophthalmology received the Medal Lecturer award from The International Society of Cornea, Stem Cells, and Ocular Surface for her lecture “Corneal transplants, flaps, lasers, bubbles: recent advances in cornea and refractive surgery,” in Catania, Italy. UC San Diego Health Sciences also awarded her the Excellence in Mentoring Award.

Catherine Y. Liu, MD, PhD, Assistant Professor of Clinical Ophthalmology, was awarded the Lanna Cheng Innovation Award for Oculoplastics Research.

Christopher Toomey, MD, PhD, Assistant Professor of Clinical Ophthalmology, was awarded the Lanna Cheng Innovation Award in recognition of outstanding Innovation in Research in Retina.

Shira L. Robbins, MD, Professor of Clinical Ophthalmology was elected President, Medical Staff UC San Diego Health System and Chair, Medical Staff Executive Committee. Also, she was appointed Section Editor for the Survey of Ophthalmology and Section Editor for the Clinical and Experimental Ophthalmology. She was listed on the 2023 San Diego Magazine’s Exceptional Women in Medicine list and 2023 San Diego County Medical Society Top Doctors list. She won Best in Show Scientific Poster at the American Association for Pediatric Ophthalmology and Strabismus annual meeting.

In November 2023, Napoleone Ferrara, MD was awarded the 2023 Keio University Medical Science Prize in Tokyo Japan for “Molecular Basis of Angiogenesis and its Application.” Keio University, Japan’s oldest private university, annually awards the prize to recognize researchers who have made outstanding and creative contributions to the fields of medicine or life sciences. It aims to promote worldwide advances in medicine and life sciences, to encourage the expansion of researcher networks throughout the world and to contribute to the well-being of mankind.

Sally Baxter, MD, MSc has been named as the recipient of the 2024 Ludwig von Servillman Clinician-Scientist Award from the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research. She was selected for the award based on her accomplishments as a young clinician scientist. The ceremony will be on May 5, 2024 in Seattle, Washington.
Robert N. Weinreb, MD, Chair and Distinguished Professor of Ophthalmology at the Viterbi Family Department of Ophthalmology and Director, Shiley Eye Institute at UC San Diego was the recipient of the World Glaucoma Association’s highest honor, the Laureate Award, at the World Glaucoma Congress (WGC) on June 28, 2023 in Rome, Italy. Comprised of 91 international glaucoma societies with more than 14,000 members, the World Glaucoma Association is a global organization for glaucoma science and care whose core purpose is to eliminate glaucoma-related disability worldwide. Only the third recipient of this prestigious award, it recognizes Weinreb’s “seminal research, meritorious service, leadership and mentorship, innovation, international contributions, public service, translation of science to practice, and lifetime achievement.” According to Neeru Gupta, MD, PhD, MBA, President, World Glaucoma Association, Professor and Chair, Department of Ophthalmology, University of British Columbia, “With unsurpassed clinical acumen and surgical excellence, Weinreb also was named in 2023 as one of the top two most influential ophthalmologists in the world (“The Power List 100” by The Ophthalmologist (UK)). The Power List was selected by an international panel of 20 distinguished judges from a total of more than 200,000 eligible ophthalmologists and more than 150,000 others in eyecare and industry worldwide.

In addition, Weinreb was an inaugural inductee into The Ophthalmologist Hall of Fame. The Hall of Fame honors this prestigious group of ophthalmologists and scientists whose impact on the field of ophthalmology will last beyond their lifetimes and are considered the first ten irrefutable giants of ophthalmology. “I am honored and humbled to receive this award,” said Weinreb. Weinreb also is a Distinguished Professor of Bioengineering (affiliate), and holder of the Morris Gleich MD Chair of Glaucoma. A graduate of Harvard Medical School, Weinreb is a clinician, surgeon, scientist, mentor and educator. Patients from throughout the world seek his medical and surgical expertise. His clinical and research interests are diverse and range from the front to the back of the eye, including the diagnosis, as well as the medical and surgical treatment of glaucoma.

Weinreb has served as President of the Association for Research in Vision and Ophthalmology, World Glaucoma Association, American Glaucoma Society, American Glaucoma Society Foundation, and Latin American Glaucoma Society. He has trained and mentored more than 170 post-doctoral fellows including 25 department chairs, as well as numerous professors in the US, Canada, Asia, Europe, South America and Australia. The recipient of numerous awards and prizes, Weinreb has had continuous NIH support throughout his career, currently as Principal Investigator of two R01 grants as well as a K12 grant for clinician-scientist career development. His h-factor for impact (148) is the world’s highest in glaucoma. In 2023, he was ranked #1 in the world for the eighth consecutive year by Expertscape for glaucoma scholarship.
While traveling through San Diego County, the Shiley EyeMobile for Children staff encountered both parents and grandparents bringing the children for their eye examinations. When asked, almost all of these individuals said that they had not had a recent eye exam – if ever. As fewer children went to school during the COVID-19 pandemic, the staff began screening and examining not only the children, but the parents and grandparents as well. The staff noticed a trend.

Upon researching the aging community in San Diego County, Robert N. Weinreb, MD saw a need for their care. The Shiley Eye Institute now hopes to meet that gap with a new adult EyeMobile for the underserved. The underserved seniors in San Diego are particularly affected by barriers such as cultural, language and comprehension of care issues, and transportation to doctors’ appointments. Limited financial resources make it difficult for the aged individual to negotiate complex service systems, as well as access low or no cost health care, according to Weinreb.

“For those patients who are unable to or cannot afford to come to the clinic, SEI will bring the clinic to them,” says Weinreb.

With an estate gift from a generous patient, the funds were obtained for a new larger EyeMobile for Children. This enabled the original 10-year-old EyeMobile to be repurposed.

The new EyeMobile will have a full-size exam room and waiting area within the vehicle. The scope of work to make the vehicle ADA compliant includes enlarging the outside door opening, adding handrails and a wheelchair lift, as well as installing new flooring. The program will have a full-time manager/driver/vision screener and an optometrist. Just as with the EyeMobile for Children, all care is provided at no cost to the patient. This new entity will partner with low-income and underserved senior services across San Diego County to bring quality eye care to vulnerable patients.

Evaluation, monitoring, and vision correction improves quality of life. The need for continued efforts to ensure that the underserved elderly have access to vision care services is imperative in San Diego County. The Shiley Eye Institute and Viterbi Department of Ophthalmology are dedicated to preserving the sight of the most vulnerable populations of children in San Diego County. We now wish to expand the outreach to care for underserved seniors and adults in San Diego County.

The refurbished vehicle will be completed and ready to serve the community in early 2024!
Jeffrey E. Lee, MD is an Associate Professor of Clinical Ophthalmology at UC San Diego Shiley Eye Institute and Viterbi Family Department of Ophthalmology. He is also the Program Director for the Ophthalmology Residency Program and the Clinical Service Chief of Ophthalmology at UC San Diego’s Hillcrest Hospital.

Lee earned his medical degree from UC San Diego and his undergraduate degrees in biology and economics from UC Berkeley. After a transitional internship in Internal Medicine, he continued on to complete his ophthalmology training at UC San Diego.

Lee maintains a broad and comprehensive clinical practice, including cataract surgery, and sees a diverse patient population. His chief academic interests include facial burns, orbital trauma, and ocular manifestations of HIV. Lee believes in utilizing the abundant resources of UC San Diego’s Hillcrest Hospital.

During Lee’s training years, he spent a significant amount of time caring for elderly and indigent patients at the San Diego VA Hospital and the UC San Diego Medical Center. Greatly impacted by these experiences, he endeavors to combine training with philanthropy, and is committed to programs that bring quality vision care to underserved patients.

In recognition of Lee’s exceptional commitment to education as Residency Director, he has won several teaching awards.

WHY DID YOU GO INTO MEDICINE? I was born and raised in Sacramento, California and developed a strong interest in medicine from an early age. My parents were immigrants from Hong Kong in the 1970s and came over to California as the youngest of three. My father was a pediatrician and my mother worked in the hospital. I grew up seeing the impact of medicine firsthand and was inspired to pursue a career in medicine.

WHY DID YOU GO INTO EYE CARE? Medicine grew as I worked with my father’s doctors throughout his medical journey. I was blessed to be able to make connections with various physicians through my college experience at UC Berkeley, and I began to see the significant impact physicians had on the lives of their patients and families. I began to desire a career in medicine as well, and am grateful for many of those physicians and mentors who helped guide my path.

EXPLAIN THE INTERSECTION OF YOUR CLINICAL PRACTICE AND RESIDENCY EDUCATION POSITION? Upon graduating residency at UC San Diego, I was given the opportunity to help our residency program optimize our inpatient ophthalmology consultation service. It had become a challenge to handle the significant complexity of the cases and the limited resources allotted to provide better opportunities for our residents.

In 2012, only three years after residency, I became the program director of the UC San Diego Post Graduate Year Two (PGY2) trainees. By building this strong foundation for their training, I was nominated by our leadership and our trainees to take on the program director role.

We now have stronger relationships with other services, provide outstanding care for our patients, and residents have the tools necessary to optimally handle the most challenging cases even early in their training. Thus, our focus was on building this strong foundation for their training. This early empowerment for the residents brought about such a positive change in our patients, our residents, and our department. Furthermore, because I worked diligently with the residents in building this strong foundation for their training, I was nominated by our leadership and our trainees to take on the program director role.

In 2021, two years after residency, I returned to my PGY2 year. We established one of the first programs in the country to provide significant primary cataract surgeries for ophthalmology residents within a few months of initiating their training. This allowed trainees to focus on surgical skills refinement over their full three years of residency. In addition to building confidence in our trainees, we also saw improved patient outcomes through our longitudinal studies. The results were published in the Journal of Cataract and Refractive Surgery (Ellis EM et al 2018).

Faculty Spotlight

Jeffrey E. Lee, MD

Associate Professor of Clinical Ophthalmology Comprehensive Ophthalmology Program Director, Ophthalmology Residency

In 2012, only three years after residency, I became the program director of the UC San Diego Post Graduate Year Two (PGY2) trainees. By building this strong foundation for their training, I was nominated by our leadership and our trainees to take on the program director role.
WHAT OPPORTUNITIES DO YOU SEE IN THE FUTURE AS RESIDENCY DIRECTOR?

Throughout my medical career, I have been blessed to be mentored by the best in Ophthalmology and guided by leaders in Medicine, Ophthalmology, and Ophthalmology education. These relationships have allowed me to help build our residency into what it is today, shaping the future of Medicine and Ophthalmology trainees to be the best they can be. My primary passion for residency education has been to empower our trainees early with the tools to lessen the steep learning curve that comes with Ophthalmology residency. As our trainees are increasingly multi-talented, extremely successful individuals, and with a plethora of amazing opportunities in our field, it will be important to help our future trainees balance their talents and resources so as not to create physician burnout. I hope to enhance and implement future physician wellness programs to help each resident reach their greatest potential. I am thankful to my Chair, department leadership, faculty, fellow program directors, residents, and many others who have provided me with the support to do this job to the best of my abilities.

HOW DO COLLABORATIONS FIT INTO YOUR ROLES?

Recently, with the integration of the Post Graduate Year 1 (PGY1) internship training, UC San Diego has just begun our partnership with the internship program at Scripps Mercy. Bringing together leadership from these two large health institutions to form a program to enhance Ophthalmology resident education has been nearly a decade in the making. Although building these bridges was challenging, it was well worth the effort to bring the best education we can for our trainees. I am so thankful for the support of our leadership at UC San Diego, as well as our Scripps partners right next door. We look forward to a wonderful partnership for decades to come!

WHAT DO YOU DO IN YOUR FREE TIME?

I love spending time with my beautiful wife, who is a dermatologist, and 4 children (3 girls and a new baby boy). We love going for walks, swimming, and trying all the best Asian restaurants around San Diego! We also enjoy traveling. Some of our favorite places include Bora Bora, Budapest, Santorini, and Banff. Although recently, most of our travels have been to Disneyland!

Derek S. Welsbie, MD, PhD, is an Associate Professor of Ophthalmology at the UC San Diego Shiley Eye Institute and Viterbi Family Department of Ophthalmology. In his clinical practice, he cares for adolescents and adults with all stages of glaucoma. In addition, he oversees an extraordinary research laboratory, focusing on the optic nerve. Welsbie studies how glaucoma leads to optic nerve injury, neurodegeneration and ultimately, vision loss. Specifically, he uses high-throughput genetic screening to comprehensively characterize the genes responsible for nerve cell death. His ultimate goal is to develop new medication and gene therapy-based neuroprotective strategies to interfere with these deleterious genes, prevent nerve cell death and improve outcomes for patients with glaucoma.

Prior to joining UC San Diego Health in 2016, Welsbie was a faculty member at the Johns Hopkins University Wilmer Eye Institute, where he won the Shafer Prize for innovative glaucoma research from the Glaucoma Research Foundation and was named Assistant Professor of the Year (2015). In 2019, Welsbie’s laboratory was selected for the Catalyst for a Cure Consortium by the Glaucoma Research Foundation. He has been awarded multiple resident teaching awards including the Whitehill Prize. He also served as the Stephen J. Ryan Assistant Chief of Service and continues to have an interest in resident and medical student education.

Welsbie completed a residency in Ophthalmology and fellowship training in Glaucoma at the Wilmer Eye Institute at Johns Hopkins University. He earned his medical degree and doctorate in molecular biology from the David Geffen School of Medicine at UCLA.

Derek S. Welsbie, MD, PhD
Associate Professor of Ophthalmology
Glaucoma
Glaucoma is a neurodegenerative disease, defined by the loss of optic nerve cells, yet all of our treatments (i.e., laser, eye drops and surgery) focus on nerve cells. The next step is to use a variety of genetic techniques, including molecular scissors known as CRISPRs, to interfere with the function of each gene in the genome. One by one, we “perturb” gene function and measure the effect on neural function and neurodegeneration. Any gene whose inhibition increases the survival of the optic nerve cells, must be playing a role in the neurodegeneration. Any gene that most will do great and retain useful vision throughout their life. I am most affected by the patients where that is not the case. Lowering eye pressure is not a perfect therapy. There are those patients who have already lost vision from glaucoma, and they ask me what can be done to improve their vision. Unfortunately, despite places that will advertise electrical therapy and stem cell therapy, there really is no good option for these patients. It would not be able to tell them something different at the end of my career. These are the stories that motivate me to come to work every day.

How do collaborations and partnerships fit into your role as a researcher? Science is just too big to do everything yourself. I am very fortunate to have numerous collaborations at other institutions like Johns Hopkins University, UC San Francisco, UC Davis and Stanford University. In fact, we are part of a group called the Catalyst for a Cure, funded by the Glaucoma Research Foundation, which is focused on collaborative research. I also have collaborations across UC San Diego in Pharmacology and within SEI, Karl Wahlin, PhD. He is an expert with stem cell-based models of the retina (i.e. organoids) and that allows my team to work with human models of glaucoma (and not just rodents).

What do you see as the next big advances in your field? It is very exciting to see developments in minimally invasive surgery. While this is safer, some specialists quip that these are also minimally effective surgeries. Work by my colleagues at SEI like Alex Huang, MD, PhD are showing how to potentially target the surgeries to get more bang for your buck. We have just seen one of the first sustained delivery devices, giving us hope that we can do better than requiring patients to take eye drops. We are also seeing developments in measuring the structure and function of the optic nerve.

What do you do in your free time? I have a wonderful family! My wife Kristi trained as a physical therapist and now works with people who have lost vision, thus we should take up a hobby that is very important. My daughter Ariana is a sophomore at Washington University in St. Louis where she is studying the intersection of psychology, cognitive science and philosophy. I have two sons, Andrew and Asher, who are in 8th and 12th grades. When we moved to San Diego, we figured we would have to learn to surf or sail. Well, the first one wasn’t going to happen so we learned to sail as a family!
Arthur J. Sit, MD, MS has been a Professor of Ophthalmology, Research Chair, and Director of the Glaucoma Fellowship at the Mayo Clinic in Rochester, Minnesota since 2005.

While Sit trained as a glaucoma fellow at the UC San Diego Shiley Eye Institute in 2005, his decision to become a clinician-scientist was solidified. He saw and “experienced the joy of working at the cutting edge of glaucoma science and clinical ophthalmology” stated Sit, under the mentorship of Robert N. Weinreb, MD.

Sit, from Toronto, Canada, did not always picture himself with a career in medicine. He completed his undergraduate education in mechanical engineering at the University of Toronto. While attending college, he worked in a laboratory where they “put him in front of a set of bovine eyes for experimentation,” stated Sit. “Luckily, I was introduced to how engineering principles could be applied to solving problems in medicine – specifically glaucoma.” Following his undergraduate studies, he pursued engineering in the private sector for a few years.

Sit noted, “Feeling the pull of research and the desire to further explore what had intrigued me about biomedical engineering, I returned to school at the Massachusetts Institute of Technology (MIT), where I studied for a master’s degree in mechanical engineering while performing research in modeling aqueous humor outflow. It was during this time I knew that I wanted to enter medicine and specifically ophthalmology. I realized that scientists and engineers can help provide the answers to problems, but it was clinician-scientists who asked the questions!”

Sit returned to the University of Toronto for medical school and ophthalmology residency. During the second half of his residency, he met Neeru Gupta, MD, PhD, MBA, an SEI alumna in glaucoma fellowship and she became his mentor. “Following in Neeru’s footsteps, I was thrilled to be accepted for a glaucoma fellowship by Dr. Weinreb, which was a truly life-changing experience. The environment at UC San Diego and the example set by Dr. Weinreb solidified my desire to become a clinician-scientist.”

Sit describes the education he received at SEI as profound, as he was part of a world-leading research institution while receiving outstanding clinical training. “I saw how an academic and intellectual environment, where any question could be asked and any answer often led to new avenues of investigation, was critical for pushing the boundaries of research.” He went on to say, “I have taken inspiration from my time at UC San Diego, first seeking out a work environment that fostered a similar intellectual curiosity, and then building a glaucoma fellowship modeled after my own experience. Further, the importance of giving back through professional service is something that I learned during my fellowship and is a critical part of my career. Even now, when faced with a career dilemma, I will ask myself, “What would Dr. Weinreb do?”

Most of Sit’s research is focused on aqueous humor dynamics and its application to understanding intraocular pressure (IOP) fluctuations and treatment mechanisms of action. His long-term research goal is to develop methods for modulating IOP fluctuations in glaucoma patients. Both research interests stemmed from work on intraocular pressure fluctuations which he performed at SEI with Dr. Weinreb and Professor John H. K. Liu, PhD. Sit stated, “Dr. Weinreb has continued to be a mentor and inspiration to me throughout my career.”

Sit’s research team developed an objective method based on image analysis of venous collapse from an externally applied pressure, combined with mathematical models from ideal tube laws. This method, combined with previously developed techniques for measuring aqueous humor flow rate and outflow facility has allowed his team to identify the mechanisms for IOP variations due to body position and circadian rhythms. They have also investigated the mechanisms of action of new treatments and identified reduction of episcleral venous pressure as a novel option for controlling IOP. More recently, his team has begun to investigate the role of ocular biomechanical properties in glaucoma and their IOP functions.
Sit states, “Too many glaucoma patients continue to have progression of their disease despite IOP reduction. We are now on the cusp of having routine continuous monitoring. I believe that this technology will transform our understanding of glaucoma by providing data about IOP fluctuations that has never been possible in glaucoma patients. This will lead to a fundamental shift in how we manage glaucoma, as the stability of IOP becomes an important goal of treatment, similar to how stability of blood glucose is an important goal in diabetes management.”

Sit’s advice to future trainees is to “Take advantage of the opportunities that are open to you. Whether it is in clinical training, research, or professional development, you will encounter numerous opportunities to learn and grow. Especially early in your career, it is critical to seize these opportunities. Don’t let these opportunities pass without at least considering them.”

“Also, never stop learning or questioning the status quo. Every patient that you see, surgery that you perform, paper that you read or write, is an opportunity to learn and identify opportunities for change. Constantly being curious is what will keep your work interesting,” stated Sit. “And finally, take the time to pause and enjoy life. You have chosen a career that truly lets you do it all.”

Outside of work Sit spends time with his family, with whom he shares a passion for travel. He credits being an academic glaucoma specialist for providing numerous opportunities to travel around the world and explore new cities, countries, and cultures.

Christopher Leung, MD, MSc, 2007 glaucoma alumnus, is currently Chair, Department of Ophthalmology, The University of Hong Kong, Director, HKU Eye Centre, and Chief of Service, Department of Ophthalmology, Queen Mary Hospital in Hong Kong.

Leung is a clinician-scientist whose research focuses on glaucoma detection and diagnostic imaging of the optic nerve. He received a MSc in Molecular Medicine at Imperial College London and obtained his medical training (MB ChB) and doctoral education (MD) from the Chinese University of Hong Kong (CUHK). Awarded the Croucher Foundation Fellowship, he completed a clinical and research fellowship at the Hamilton Glaucoma Center, UC San Diego. The research team led by Leung has been playing a leading role in introducing key concepts and new technologies for early diagnosis of glaucoma and detection of its progression. His research group also investigates new treatment strategies for neuroprotection and neuroregeneration in glaucoma and optic neuropathies.

“I am profoundly thankful to my mentor Robert N. Weinreb, MD. His mentorship has been pivotal in my career progression, unlocking invaluable opportunities and enhancing my understanding of glaucoma. Our paths first crossed during the travel grant recipient reception at the inaugural World Glaucoma Congress in Vienna, Austria, stated Leung. “It was there that I was granted the extraordinary opportunity to spend 18 enriching months as a clinical and research fellow at UC San Diego under his tutelage. This fellowship experience was nothing short of transformative. Not only did I directly contribute to glaucoma research, but...”

Distinguished International Alumnus

CHRIS LEUNG, MD, MSc

Christopher Leung, MD, MSc, 2007 glaucoma alumnus, is currently Chair, Department of Ophthalmology, The University of Hong Kong, Director, HKU Eye Centre, and Chief of Service, Department of Ophthalmology, Queen Mary Hospital in Hong Kong.

Leung is a clinician-scientist whose research focuses on glaucoma detection and diagnostic imaging of the optic nerve. He received a MSc in Molecular Medicine at Imperial College London and obtained his medical training (MB ChB) and doctoral education (MD) from the Chinese University of Hong Kong (CUHK). Awarded the Croucher Foundation Fellowship, he completed a clinical and research fellowship at the Hamilton Glaucoma Center, UC San Diego. The research team led by Leung has been playing a leading role in introducing key concepts and new technologies for early diagnosis of glaucoma and detection of its progression. His research group also investigates new treatment strategies for neuroprotection and neuroregeneration in glaucoma and optic neuropathies.

“I am profoundly thankful to my mentor Robert N. Weinreb, MD. His mentorship has been pivotal in my career progression, unlocking invaluable opportunities and enhancing my understanding of glaucoma. Our paths first crossed during the travel grant recipient reception at the inaugural World Glaucoma Congress in Vienna, Austria, stated Leung. “It was there that I was granted the extraordinary opportunity to spend 18 enriching months as a clinical and research fellow at UC San Diego under his tutelage. This fellowship experience was nothing short of transformative. Not only did I directly contribute to glaucoma research, but...”
I also had the chance to be part of an intellectually stimulating environment. The fellowship was an excellent platform for learning from some of the brightest minds in glaucoma. Undoubtedly, the time spent at UCSD under Professor Weinreb’s mentorship not only opened doors for me but also cemented my passion and commitment to glaucoma research.

Leung believes that UC San Diego has successfully shaped the careers of hundreds of eye specialists and vision scientists across the globe. A distinct advantage of receiving education and training at UC San Diego lies in the opportunity to tap into its robust international network. This network, thoughtfully cultivated over several decades, provides invaluable links to professionals, institutes, and resources, thereby fostering a vibrant environment for collaborative research and patient care. Leung notes, “Personally and professionally, I benefit from such connections which has not only enhanced the educational experience but also paved the way for partnerships, mutually beneficial collaborations, and the exchange of innovative ideas and practices in ophthalmology. This interconnectivity is an integral part of the UC San Diego experience, opening a world of possibilities for those who walk its corridors.”

Leung’s notable research contributions that he has published include the detection of focal retinal nerve fiber layer (RNFL) defects in early glaucoma and monitoring of progressive RNFL thinning in advanced glaucoma remains difficult from the assessment of topographic RNFL thickness. With retinal optical texture analysis (ROTA), the trajectorial details of individual axonal fiber bundles can be uncovered to allow intuitive visualization of RNFL defects that would otherwise be missed by conventional topographic RNFL thickness analysis and red-free photography. Contrary to the conventional belief that the fovea and macula are not affected until the late stages of glaucoma, ROTA demonstrated the axonal fiber bundles over the macula and fovea are commonly involved in early glaucoma with 70% of patients with early glaucoma had papillomacular and/or papillofoveal bundle defects. ROTA has provided an intuitive and reliable approach to discern different levels of optic nerve damage that may reset the paradigm in the diagnostic evaluation and management of glaucoma.

Leung believes that collaborations and partnerships create avenues for shared knowledge and a comprehensive understanding of clinical challenges, which then leads to the development of innovative solutions. Leung states, “Working closely with other healthcare professionals, vision scientists and engineers helps me to translate innovations and deliver the best possible patient care.” One recent example is their partnership with optical coherence tomography industrial partners, Orbis Hong Kong and Orbis International to implement their patented invention – retinal nerve fiber layer optical texture analysis (ROTA) – (U.S. Patent 10,918,275; Leung CKS, Tan AEN, Weinreb RN, et al. Diagnostic assessment of glaucoma and non-glaucomatous optic neuropathies via optical texture analysis of the retinal nerve fiber layer. Nat Biomed Eng. 2022;6:593-604) in a territory-wide glaucoma screening project in Hong Kong. The completion of the project will identify undiagnosed patients with glaucoma and inform the prevalence and risk factors of glaucoma in Hong Kong.

“I think the next big advances would likely reside in neuroprotective and neurodegenerative therapies for patients with glaucoma. We have heard exciting developments on using various nicotinamide adenine dinucleotide (NAD) augmentation strategies to restore NAD levels and optic nerve function in laboratory studies and clinical trials. Another potential neuroprotective treatment under active investigation involves intraocular implants that deliver a steady stream of cilary neurotrophic factor, protecting against damage to the optic nerve in glaucoma. Initial studies have shown promising results, with the implants being safe, well-tolerated, and effective in preserving the optic nerve,” Leung concluded.
Blind Infant Receives the Gift of Sight

Jose Maria Partida, MD, a San Diego primary care physician and patient of Shiley Eye Institute’s (SEI) Manuel Puig-Llano, MD, brought a blind child, Nahomi, to his attention. She was born with cataracts in both eyes. Partida met Nahomi and her mother, Katia, on one of his regular trips to feed impoverished individuals in Tijuana, Mexico. He and Puig-Llano worked hard to get Nahomi and her mother Katia travel visas to receive care at SEI. Once Nahomi and Katia received visas, Partida drove them back and forth from Tijuana while acting as Katia’s interpreter during the appointments.

Puig-Llano reached out to Chris W. Heichel, MD, a cornea and cataract specialist at SEI, to assist with treating the child. Upon examining Nahomi, Heichel concluded that she needed surgery right away to remove her cataracts. Post-surgery Nahomi, for the first time, was able to see her mother’s face! Now when she sees her mother’s hands, she reaches out to grab them! Nahomi and Katia returned to Tijuana following her procedure but have since come back to SEI for post-operative appointments with Heichel and Puig-Llano.

In a letter from Partida following the surgery, he wrote, “Witnessing the successful outcome and giving this child the opportunity to see the world has filled our hearts with immense joy. We are profoundly grateful for the exceptional level of care and support you have extended to this family throughout this challenging journey.”

San Diego native Raquel Alim developed a passion for art as a young child, but it became challenging when at age 12 she was diagnosed with retinitis pigmentosa (RP), a genetic eye disease causing gradual vision loss. Alim was eventually declared legally blind and could no longer see the pencil marks on her sketch pad. She stopped creating art and lost hope in ever creating art again.

Later in life, things took a positive turn for Alim when she came to the Shiley Eye Institute (SEI) to see Shyamanga Borooah, MBBS, PhD. After having been evaluated by over ten retina specialists since the age of 12, Alim immediately noticed a difference with Borooah. She stated, “Dr. Borooah did something for me that no physician had ever done before. He saw me as a person, asked about my mental health, and let me know about services that are out there.”

Prior to meeting Borooah, Alim also developed cataracts and surgery was the only way to remove them. Needing surgery, Alim was referred to Natalie A. Afshari, MD at SEI.

While waiting in the pre-operative area in the SEI surgery suite right before her surgery, Afshari circled the eye that would be operated on with a marker. Instead of throwing this marker away after its use, Afshari offered it to Alim, and she accepted. Following Alim’s surgery, she was able see and began to doodle with that same marker, rekindling her love of art!

Today, Alim is an artist producing paintings for her Unblurred Collection. She donates a portion of the profit from her paintings to organizations like the San Diego Center for the Blind and Foundation Fighting Blindness. The encouragement and services facilitated at SEI by Borooah and Afshari were crucial in renewing her sense of hope and reigniting her passion for creating art.
As an eight-year patient at Shiley it recently occurred to me that although I have said what follows to many doctors, nurses, and technicians, I have never directly addressed the people who first greet us and help us with our check-in and appointments and such. Your “greeters,” if I may, have and continue to be, in close contact with very many patients—probably as much as if not more than the average clinician, and so the words of praise that follow are equally applicable to them as well.

For the past three years, no single segment of our society has been subjected to such constant stress as the members of our medical community. You have performed magnificently. You have continued to improve—indeed, save—lives while placing your own in harm’s way. As an elder and beneficiary, I say “God bless you and thank you for your service.”

Following Caganich’s procedure an unrelated retinal issue emerged, which was promptly identified, and addressed by Shyamanga Borooah, MBBS, PhD. After same-day surgery and follow-up appointments, she was given a clean bill of health in the spring of 2023. Grateful for the exceptional care provided by both Heichel and Borooah, she expressed her appreciation for their commitment that went “above and beyond.”

In the fall of 2023, Caganich experienced a burning sensation in her eyes due to a rare allergic reaction to a new medication she was taking, resulting in a visit to the ER. In the ER she was diagnosed with uveitis by a SEI resident. Currently she is seeking specialized treatment from uveitis expert Lingling Huang, MD, PhD at SEI.

Throughout Caganich’s vision journey, she has remained thankful to SEI. “Words cannot sufficiently express my deep gratitude for my doctors and the entire Shiley team,” said Caganich.

As an eight-year patient at Shiley it recently occurred to me that although I have said what follows to many doctors, nurses, and technicians, I have never directly addressed the people who first greet us and help us with our check-in and appointments and such. Your “greeters,” if I may, have and continue to be, in close contact with very many patients—probably as much as if not more than the average clinician, and so the words of praise that follow are equally applicable to them as well.

Following Caganich’s procedure an unrelated retinal issue emerged, which was promptly identified, and addressed by Shyamanga Borooah, MBBS, PhD. After same-day surgery and follow-up appointments, she was given a clean bill of health in the spring of 2023. Grateful for the exceptional care provided by both Heichel and Borooah, she expressed her appreciation for their commitment that went “above and beyond.”

In the fall of 2023, Caganich experienced a burning sensation in her eyes due to a rare allergic reaction to a new medication she was taking, resulting in a visit to the ER. In the ER she was diagnosed with uveitis by a SEI resident. Currently she is seeking specialized treatment from uveitis expert Lingling Huang, MD, PhD at SEI.

Throughout Caganich’s vision journey, she has remained thankful to SEI. “Words cannot sufficiently express my deep gratitude for my doctors and the entire Shiley team,” said Caganich.

For the past three years, no single segment of our society has been subjected to such constant stress as the members of our medical community. You have performed magnificently. You have continued to improve—indeed, save—lives while placing your own in harm’s way. As an elder and beneficiary, I say “God bless you and thank you for your service.”

Although all the people at both check-in areas have always been courteous and respectful, I have noticed over the course of these years, one person who consistently goes above and beyond the call of duty. I have seen Andrea Lloyd, Front Desk Supervisor, offer an arm to an elderly or handicapped patient or render a kind word of encouragement or a friendly wave to another. I doubt that these empathetic qualities are mentioned in Ms. Lloyd’s formal job description, but I am sure they have brought an increased humaneness to many of us who are at times intimidated by aspects of the healthcare process.

Harvey 2023
Dear Dr. Kikkawa,

I am James Zhao, MD, your former patient Yan Wang’s husband, whose life you profoundly impacted with your exceptional medical insight. I write this letter not only in my capacity as a fellow physician but also as a deeply grateful husband.

You might remember Yan as your patient from eight years ago, when she was a postdoctoral researcher at Shiley Eye Center focusing on optic nerve regeneration. Her unique case presented us with a leadership position in oncology clinical research at the University of Michigan. Since then, she has dedicated her career to clinical research in head and neck cancer. She currently holds a leadership position in oncology clinical research at the University of Michigan. Our family’s story could have been dramatically different had it not been for your keen diagnostic prowess and compassionate care. Today, as we look at our healthy child, cherish our family moments, and pursue our fulfilling careers, we are reminded of your crucial role in our journey. We wanted to take this moment to express our deepest gratitude and let you know the far-reaching impact of your work.

Wagner works in conjunction with SEI physician scientists Shyamanga Borooah, MBBS, PhD, on patients with retinal dystrophies and Nathan Scott, MD, MPP, on patients with cancer involving the eye (ocular oncology). She talks patients through genetic test results and helps them understand what their genetic findings mean for them and their families. All patients seen in the retinal dystrophy clinic who have a confirmed or expected diagnosis of inherited retinal dystrophy can pursue genetic testing and counseling with her.

“I find profound joy in connecting with patients. It is an privilege to contribute to their care by unraveling the genetic intricacies that shape their ocular health,” said Wagner.

Wagner earned her MS in Genetic Counseling at Boston University School of Medicine. Previous clinical roles include working as a telehealth genetic counselor at the genetic testing laboratory Invitae and as an ocular genetic counselor at Massachusetts Eye and Ear in Boston. Her research experience includes serving as a rare disease research assistant at Harvard Medical School, a clinical research assistant at the Hospital for Special Surgery, and a research scholar at Ludwig Maximilian University of Munich, Germany.

In addition, Wagner is a volunteer biocurator for multiple groups related to retinal conditions at the National Institutes of Health (NIH) and Clinical Genome Resource (ClinGen). At ClinGen, she evaluates clinical evidence and reviews the scientific literature to help determine which genes are causative of inherited eye conditions. Sometimes, SEI patients come back with test reports that show genes that she has personally consulted on, which helps with the interpretation of those patient results.

With warmest regards,
Zhenyang (James) Zhao, MD
Kellogg Eye Center, University of Michigan

A Decade of Gratitude: The Journey that Began with Your Diagnosis

Dear Dr. Kikkawa,

I am James Zhao, MD, your former patient Yan Wang’s husband, whose life you profoundly impacted with your exceptional medical insight. I write this letter not only in my capacity as a fellow physician but also as a deeply grateful husband.

You might remember Yan as your patient from eight years ago, when she was a postdoctoral researcher at Shiley Eye Center focusing on optic nerve regeneration. Her unique case presented us with a leadership position in oncology clinical research at the University of Michigan. Since then, she has dedicated her career to clinical research in head and neck cancer. She currently holds a leadership position in oncology clinical research at the University of Michigan. Our family’s story could have been dramatically different had it not been for your keen diagnostic prowess and compassionate care. Today, as we look at our healthy child, cherish our family moments, and pursue our fulfilling careers, we are reminded of your crucial role in our journey. We wanted to take this moment to express our deepest gratitude and let you know the far-reaching impact of your work.

Wagner works in conjunction with SEI physician scientists Shyamanga Borooah, MBBS, PhD, on patients with retinal dystrophies and Nathan Scott, MD, MPP, on patients with cancer involving the eye (ocular oncology). She talks patients through genetic test results and helps them understand what their genetic findings mean for them and their families. All patients seen in the retinal dystrophy clinic who have a confirmed or expected diagnosis of inherited retinal dystrophy can pursue genetic testing and counseling with her.

“I find profound joy in connecting with patients. It is an privilege to contribute to their care by unraveling the genetic intricacies that shape their ocular health,” said Wagner.

Wagner earned her MS in Genetic Counseling at Boston University School of Medicine. Previous clinical roles include working as a telehealth genetic counselor at the genetic testing laboratory Invitae and as an ocular genetic counselor at Massachusetts Eye and Ear in Boston. Her research experience includes serving as a rare disease research assistant at Harvard Medical School, a clinical research assistant at the Hospital for Special Surgery, and a research scholar at Ludwig Maximilian University of Munich, Germany.

In addition, Wagner is a volunteer biocurator for multiple groups related to retinal conditions at the National Institutes of Health (NIH) and Clinical Genome Resource (ClinGen). At ClinGen, she evaluates clinical evidence and reviews the scientific literature to help determine which genes are causative of inherited eye conditions. Sometimes, SEI patients come back with test reports that show genes that she has personally consulted on, which helps with the interpretation of those patient results.

With warmest regards,
Zhenyang (James) Zhao, MD
Kellogg Eye Center, University of Michigan

The Viterbi Family Department of Ophthalmology and the Shirley Eye Institute (SEI) welcomes Naomi Wagner, MS, CGC, as a Clinical and Research Genetic Counselor. Wagner specializes in inherited retinal dystrophies and ocular oncology. Genetic counselors are essentially the first point of contact, providing of genetic information which can have predictive family planning and therapeutic implications. According to a 2023 “Professional Status Survey” from the National Society of Genetic Counselors, there are only 22 genetic counselors in the US and Canada that have Ophthalmology as their primary area of practice. Wagner stated, “It is quite rare to have an ophthalmic genetic counselor on site in a clinical setting. Based on the recent survey data, that is less than 1% of the total profession of genetic counselors in North America.”

Wagner works in conjunction with SEI physician scientists Shyamanga Borooah, MBBS, PhD, on patients with retinal dystrophies and Nathan Scott, MD, MPP, on patients with cancer involving the eye (ocular oncology). She talks patients through genetic test results and helps them understand what their genetic findings mean for them and their families. All patients seen in the retinal dystrophy clinic who have a confirmed or expected diagnosis of inherited retinal dystrophy can pursue genetic testing and counseling with her.

“I find profound joy in connecting with patients. It is an privilege to contribute to their care by unraveling the genetic intricacies that shape their ocular health,” said Wagner.
Advancing Diversity & Inclusion at SEI

We are committed to cultivating a welcoming, inclusive environment for all patients, employees, faculty, and trainees.

The UC San Diego Viterbi Family Department of Ophthalmology and Shiley Eye Institute (SEI) continues to promote diversity and inclusion in clinical activities, research, education, and community service. Leading most of these efforts is the Diversity, Equity, and Inclusion (DEI) committee, co-chaired by Nathan Scott, MD, MPP, and Sally Baxter, MD, MSc.

NIH Bridge2AI Grant

In 2022, SEI secured the prestigious trans-NIH Bridge2AI grant, supporting a yearlong internship program designed to train individuals from diverse backgrounds in artificial intelligence (AI), machine learning, and biomedical research. The inaugural cohort, which commenced in the summer of 2023, includes 50% underrepresented minorities (URM). Notably, DEI co-chair Baxter, and committee member Linda Zangwill, PhD, are leading the Skills and Workforce Development Module as co-Principal Investigators.

NIH T35 Grant

SEI was also granted a National Eye Institute (NIH) T35 short-term research training grant in May 2022. This initiative facilitated the recruitment of four URM medical students for the second consecutive year, providing them financial support to complete mentored research in ophthalmology and vision science at SEI over the summer.

This year’s events promoting DEI for all SEI staff included a cultural potluck and a performing arts showcase. Additionally, the DEI committee created a cookbook featuring recipes from the different cultures among SEI employees. Unique DEI committee shirts were designed during the year to further solidify a sense of belonging amongst the team.

Beyond internal efforts, SEI faculty, staff, and trainees engaged in local outreach activities. This included conducting seminars for students, providing care to underserved individuals through the UC San Diego Free Clinic and the Shiley EyeMobile for Children, as well as contributing to broader diversity-related initiatives at UC San Diego Health Sciences and the campus.

Recognizing these collective efforts, Robert N. Weinreb, MD nominated the Shiley DEI committee for a UC San Diego Inclusive Excellence Award. These awards commend individuals and groups for their leadership in advancing equity, diversity, and inclusion, aligning with the UC San Diego Principles of Community. The nomination reflects SEI’s strong commitment to fostering a diverse and inclusive environment.
Juan Arias, MBA, Assistant Director of Ophthalmology Services at the Shiley Eye Institute (SEI), was selected to participate in the 2023 UC San Diego Health Leadership Academy (HLA). As part of a team comprised of physicians and administrators, Arias contributed to a proposal aiming to improve mammography accessibility at UC San Diego, resulting in a secured $1 million funding commitment.

Arias’s team project focused on optimizing operational hours at the UC San Diego Health Koman Family Outpatient Pavilion. Additionally, the team proposed implementing a mobile unit to address the impact of zip code demographics and clinic locations, aiming to bridge the gap and promote healthcare equality.

The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute (SEI) welcomes Amanda Kuczka, BSN, RN, MBA, CNOR as our new Operating Room Nurse Manager. She is responsible for ensuring high standards of patient care and safety, as well as the effective functioning of the operating room.

"The Navy Nurse Corps shaped me from an inexperienced ward nurse to a perioperative leader with diverse and rewarding life and career experience," stated Kuczka.

Brendan Kremer
Chief Operating Officer
UC San Diego Health

Barbara Hamilton
Director of Sustainability and Energy
UC San Diego Health

Certification Level: Gold

The UC San Diego Health Sustainability Department proudly presents this certificate for achievements in leadership and sustainability, supporting UC Sustainable Goals, and helping to create a culture of health for all environments.

Congratulations!

Welcome OR Nurse Manager

SEI @ UCSD Leadership Academy

SEI Is Green Certified

Shiley Eye Institute and the Viterbi Family Department of Ophthalmology at UC San Diego participated in a Green Clinic Certification audit for sustainability and achieved a GOLD status! SEI is the largest ambulatory clinic on the UC San Diego Health campus, and this is a great accomplishment for the ophthalmology faculty and staff working together. This is a voluntary audit in which our faculty and staff are committed to creating less trash, recycling all that we are able to and using less energy during clinic hours. Congratulations!

SEI Is Green Certified
Welcome New Faculty
LINGLING HUANG, MD, PhD

The Viterbi Family Department of Ophthalmology and Shiley Eye Institute (SEI), UC San Diego welcomes Lingling Huang, MD, PhD, as an Assistant Professor of Ophthalmology. Huang is board-certified and specializes in treating both pediatric and adult patients with infectious or autoimmune uveitis.

Huang earned her PhD in Molecular Cancer Biology at Duke University, then earned her medical degree at Washington University School of Medicine in St. Louis. She completed her intern year at the Massachusetts General Hospital, and subsequently was an ophthalmology resident at UC San Diego where she was a Chief Resident. She then completed a Uveitis Fellowship at the Casey Eye Institute at Oregon Health & Science University.

As a physician-scientist, Huang’s focus is on all forms of uveitis or inflammation. In Huang’s research at SEI, she is utilizing data from electronic health records and imaging tests to enhance and personalize clinical outcomes using artificial intelligence (AI) for patients with uveitis.

Welcome Faculty
LINGLING HUANG, MD, PhD
Assistant Professor of Ophthalmology
Uveitis and Orbital Inflammatory Diseases

Every year, Shiley Eye Institute specialists are honored to be named as being “the best” by major national and local organizations.

FACULTY

The Ophthalmologist
Expertscape
Castle Connolly
San Diego Magazine
TOP Doctors

U.S. News & World Report
Best Doctors
SuperDoctors
Newsweek

GLAUCOMA
Glaucoma surgery (conventional and minimally invasive), medical management of glaucoma; biology of aqueous outflow; mechanisms of optic nerve damage and neuroprotection in glaucoma; visual function; cataract surgery.

Robert N. Weinreb, MD
Chair & Distinguished Professor, Viterbi Family Department of Ophthalmology
Director, Shiley Eye Institute
Director, Hamilton Glaucoma Center
Distinguished Professor of Bioengineering
Morris Gleich, MD Chair in Glaucoma
Professor of Ophthalmology, Emeritus
CORNEA & REFRACTIVE
Corneal transplantations and cataract surgeries.
Stuart I. Brown, MD
Christopher Bowd, PhD
Research Scientist of Ophthalmology
Director of the Hamilton Glaucoma Center-based Visual Field Assessment Center
Co-Director of the Hamilton Glaucoma Center-based Imaging Data Evaluation and Analysis (IDEA) Center
GLAUCOMA
Early detection and monitoring of glaucoma; machine learning classifier analyses of imaging and visual function measurements.
Shyamanga Borooah, MBBS, MRCP (UK), MRCSEd, FRCOphth, PhD
Assistant Professor of Clinical Ophthalmology
Glen Burn Eye Care Center
Shyamanga Borooah, MBBS, MRCP (UK), MRCSEd, FRCOphth, PhD
Assistant Professor of Clinical Ophthalmology
Glen Burn Eye Care Center
Christopher Bowd, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Radha Ayyagari, PhD
Professor of Ophthalmology
Vice Chair for Education, Department of Ophthalmology
Chief, Division of Cornea and Refractive Surgery
Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley
CORNEA & REFRACTIVE
Fuchs dystrophy; cataract surgery; corneal transplantation; endothelial keratoplasty (DSAEK & DMEK); Intacs and collagen crosslinking for keratoconus; laser refractive surgery, including LASIK and PRK; surgical and medical diseases of cornea.
Natalie A. Afshari, MD, FACS
Professor of Ophthalmology & Pathology
Chief of Ophthalmic Molecular Diagnostic Laboratory
Director of the Downtown San Diego Lions Club Bulbank for Vision
Viterbi Family Chair of Ophthalmic Genetics
GENETICS
Molecular genetics of macular and retinal dystrophy; biological mechanisms underlying retinal diseases; age-related macular degeneration; diabetic retinopathy; and glaucoma.
Andrew S. Camp, MD
Assistant Professor of Ophthalmology
Acting Chief of the Ophthalmology Section at the Veterans Administration Medical Center
GLAUCOMA
Adult and pediatric glaucoma.

Mark Christopher, PhD
Assistant Project Scientist of Ophthalmology

Jian Do, MD, PhD
Assistant Professor of Ophthalmology

Napoleone Ferrara, MD
Distinguished Professor of Ophthalmology and Pathology
Senior Deputy Director for Basic Sciences, UC San Diego Moores Cancer Center
Ben and Wanda Hildyard Chair for Diseases of the Eye

Henry A. Ferreyra, MD
Clinical Professor of Ophthalmology

William R. Freeman, MD
Distinguished Professor of Ophthalmology

Michael H. Goldbaum, MD
Professor of Ophthalmology in Residence, Emeritus

David B. Granet, MD, MHCM, FACS, FAAO, FAAP
Professor of Clinical Ophthalmology and Pediatrics
Vice Chair, Department of Ophthalmology
Anne Ratner Chair of Pediatric Ophthalmology
Director, Anne F. & Abraham Ratner Children’s Eye Center
Director, Division of Pediatric Ophthalmology & Eye Alignment

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Pediatric ophthalmology and strabismus, adult eye movement problems, strabismus surgery, childhood eye misalignments & disorders, and nystagmus.

David B. Granet, MD, MHCM, FACS, FAAO, FAAP
Professor of Clinical Ophthalmology and Pediatrics
Vice Chair, Department of Ophthalmology
Anne Ratner Chair of Pediatric Ophthalmology
Director, Anne F. & Abraham Ratner Children’s Eye Center
Director, Division of Pediatric Ophthalmology & Eye Alignment

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Pediatric ophthalmology and strabismus, adult eye movement problems, strabismus surgery, childhood eye misalignments & disorders, and nystagmus.

Jiun Do, MD, PhD
Assistant Professor of Ophthalmology

William R. Freeman, MD
Distinguished Professor of Ophthalmology

Henry A. Ferreyra, MD
Clinical Professor of Ophthalmology

Andrew S. Camp, MD
Assistant Professor of Ophthalmology
Acting Chief of the Ophthalmology Section at the Veterans Administration Medical Center
GLAUCOMA
Adult and pediatric glaucoma.

Mark Christopher, PhD
Assistant Project Scientist of Ophthalmology

Jian Do, MD, PhD
Assistant Professor of Ophthalmology

Napoleone Ferrara, MD
Distinguished Professor of Ophthalmology and Pathology
Senior Deputy Director for Basic Sciences, UC San Diego Moores Cancer Center
Ben and Wanda Hildyard Chair for Diseases of the Eye

Henry A. Ferreyra, MD
Clinical Professor of Ophthalmology

William R. Freeman, MD
Distinguished Professor of Ophthalmology

Michael H. Goldbaum, MD
Professor of Ophthalmology in Residence, Emeritus

David B. Granet, MD, MHCM, FACS, FAAO, FAAP
Professor of Clinical Ophthalmology and Pediatrics
Vice Chair, Department of Ophthalmology
Anne Ratner Chair of Pediatric Ophthalmology
Director, Anne F. & Abraham Ratner Children’s Eye Center
Director, Division of Pediatric Ophthalmology & Eye Alignment

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Pediatric ophthalmology and strabismus, adult eye movement problems, strabismus surgery, childhood eye misalignments & disorders, and nystagmus.
Clinical Professor of Ophthalmology

NEURO-OPHTHALMOLOGY
Optic nerve disease; double vision; pupillary disorders; demyelinating diseases; visual abnormalities accompanying stroke.

Lanning Kline, MD

Distinguished Professor of Clinical Ophthalmology and Plastic Surgery
Vice Chair for Clinical Services, Department of Ophthalmology
Chief, Division of Oculofacial Plastic and Reconstructive Surgery
Dr. Trude Kahn Hollander Chair in Ophthalmology

OPHTHALMIC PLASTIC & RECONSTRUCTIVE SURGERY
Oculofacial surgery; eyelid, lacrimal & orbital surgery; thyroid eye disease (orbital decompression & eyelid surgery); craniofacial disorders involving the eyelids & orbits; orbital & eyelid tumors; facial aesthetics - soft tissue fillers & injectables.

Don O. Kikkawa, MD, FACS

Clinical Professor of Ophthalmology

GLAUCOMA
Cellular and molecular mechanisms for neurodegeneration; neuro-inflammation, and neuroprotection in glaucoma and Alzheimer’s disease; characterization of melanopsin-expressing retinal ganglion cell-mediated multiscale connectome in Alzheimer’s disease.

Won-Kyu “Daniel” Ju, PhD

Assistant Professor of Ophthalmology

UVEITIS
Pediatric or adult onset uveitis, infectious uveitis, and autoimmune uveitis.

Lingling Huang, MD, PhD

Clinical Professor of Ophthalmology

CORNEA & REFRACTIVE
Cataract surgery; dry eye/pterygium; cornea transplantation; refractive surgery/LASK.

Weldon W. Haw, MD

Clinical Professor of Ophthalmology

CORNEA & REFRACTIVE
Cataract transplantations and keratoprosthesis; challenging cataract and IOL surgeries; LASK, Intacs, and Visian ICL advanced techniques in laser and refractive surgery; keratoconus ocular surface tumors; limbal stem cell transplantation.

Chris W. Heichel, MD, FACS

Clinical Professor of Ophthalmology

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Comprehensive pediatric ophthalmology and strabismus including pediatric cataracts, strabismus/eye misalignment/ double vision including adjustable suture strabismus surgery, amblyopia, nasolacrimal duct disorders (tearing problems), congenital eye syndromes, and systemic diseases affecting the eyes.

Lauren Hennein, MD

Associate Clinical Professor of Ophthalmology

ALFRED VOGT CHAIR IN OPHTHALMOLOGY
Glaucoma, cataracts, and ocular changes during space flight.

Alex A. Huang, MD, PhD

Associate Professor of Ophthalmology

GLAUCOMA
Glaucoma, cataracts, and ocular changes during space flight.

Lingling Huang, MD, PhD

Assistant Professor of Ophthalmology

UVEITIS
Pediatric or adult onset uveitis, infectious uveitis, and autoimmune uveitis.

Lingling Huang, MD, PhD

Clinical Professor of Ophthalmology

CORNEA & REFRACTIVE
Cataract surgery; dry eye/pterygium; cornea transplantation; refractive surgery/LASK.

Weldon W. Haw, MD

Clinical Professor of Ophthalmology

CORNEA & REFRACTIVE
Cataract transplantations and keratoprosthesis; challenging cataract and IOL surgeries; LASK, Intacs, and Visian ICL advanced techniques in laser and refractive surgery; keratoconus ocular surface tumors; limbal stem cell transplantation.

Chris W. Heichel, MD, FACS

Clinical Professor of Ophthalmology

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Comprehensive pediatric ophthalmology and strabismus including pediatric cataracts, strabismus/eye misalignment/ double vision including adjustable suture strabismus surgery, amblyopia, nasolacrimal duct disorders (tearing problems), congenital eye syndromes, and systemic diseases affecting the eyes.

Lauren Hennein, MD

Associate Clinical Professor of Ophthalmology

ALFRED VOGT CHAIR IN OPHTHALMOLOGY
Glaucoma, cataracts, and ocular changes during space flight.

Alex A. Huang, MD, PhD

Associate Professor of Ophthalmology

ALFRED VOGT CHAIR IN OPHTHALMOLOGY
Glaucoma, cataracts, and ocular changes during space flight.

Lingling Huang, MD, PhD

Assistant Professor of Ophthalmology

UVEITIS
Pediatric or adult onset uveitis, infectious uveitis, and autoimmune uveitis.

Lingling Huang, MD, PhD

Clinical Professor of Ophthalmology

CORNEA & REFRACTIVE
Cataract surgery; dry eye/pterygium; cornea transplantation; refractive surgery/LASK.

Weldon W. Haw, MD

Clinical Professor of Ophthalmology

CORNEA & REFRACTIVE
Cataract transplantations and keratoprosthesis; challenging cataract and IOL surgeries; LASK, Intacs, and Visian ICL advanced techniques in laser and refractive surgery; keratoconus ocular surface tumors; limbal stem cell transplantation.

Chris W. Heichel, MD, FACS

Clinical Professor of Ophthalmology

PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Comprehensive pediatric ophthalmology and strabismus including pediatric cataracts, strabismus/eye misalignment/ double vision including adjustable suture strabismus surgery, amblyopia, nasolacrimal duct disorders (tearing problems), congenital eye syndromes, and systemic diseases affecting the eyes.

Lauren Hennein, MD

Associate Clinical Professor of Ophthalmology

ALFRED VOGT CHAIR IN OPHTHALMOLOGY
Glaucoma, cataracts, and ocular changes during space flight.

Alex A. Huang, MD, PhD

Associate Professor of Ophthalmology

ALFRED VOGT CHAIR IN OPHTHALMOLOGY
Glaucoma, cataracts, and ocular changes during space flight.

Lingling Huang, MD, PhD

Assistant Professor of Ophthalmology

UVEITIS
Pediatric or adult onset uveitis, infectious uveitis, and autoimmune uveitis.
Bobby S. Korn, MD, PhD, FACS
Professor of Clinical Ophthalmology and Plastic Surgery
OPHTHALMIC PLASTIC & RECONSTRUCTIVE SURGERY
Cosmetic and reconstructive surgery; blepharoplasty; ptosis surgery; congenital birth defects; endoscopic forehead lifting; thyroid eye disease management; optic nerve sheath fenestration/decompression; eyelid and orbital tumors and cancers; lacrimal tear outflow system disorders; bulging or proptosis of eyes; reconstruction of eyelids post cancer removal; reconstruction after trauma/eye injuries; facial fillers and skin rejuvenation.

Jeffrey E. Lee, MD
Associate Clinical Professor of Ophthalmology
Program Director, Ophthalmology Residency
COMPREHENSIVE OPHTHALMOLOGY
Facial burns; orbital trauma; ocular manifestations of HIV.

John H. K. Liu, PhD
Professor of Ophthalmology
Directors, Glaucoma Sleep Laboratory
GLAUCOMA
Hypothesis testing, proteomics and genomics; the role of blood-brain barrier dysfunction in Alzheimer’s disease.

Catherine Y. Liu, MD, PhD
Assistant Professor of Clinical Ophthalmology
OPHTHALMIC PLASTIC & RECONSTRUCTIVE SURGERY
Role of glaucoma imaging in early detection and monitoring of the disease.

Sasan Moghimi, MD
Assistant Professor of Clinical Ophthalmology
OPHTHALMIC PLASTIC & RECONSTRUCTIVE SURGERY
Ptosis surgery; blepharoplasty; lacrimal disease and surgery; eyelid and orbital oncology; blepharoptosis and hemifacial spasm; orbital fractures; craniofacial disorders involving the eyelid and orbit; pediatric oculoplastic surgery; facial rejuvenation.

Mansoor Movaghar, MD
Associate Clinical Professor of Ophthalmology
GLAUCOMA
Role of glaucoma imaging in early detection and monitoring of the disease; angle-closure glaucoma diagnosis and treatment.

Eric Nudelman, MD, PhD
Associate Professor of Clinical Ophthalmology
Co-Director, Retina Division
Vitreoretinal diseases, including AMD, diabetic eye disease; retinal vein occlusions; retinal detachments; proliferative vitreoretinopathy, macular holes & epiretinal membranes; pediatric vitreoretinal diseases; retinopathy of prematurity; familial exudative vitreoretinopathy; Coats disease; fetal vascular syndromes; & intracranial trauma. Developmental angiogenesis.
Manuel Puig-Llano, MD, FACS, FASKS
Clinical Professor of Ophthalmology
COMPREHENSIVE OPHTHALMOLOGY

Shira L. Robbins, MD, FAAC, FAAP
Professor of Clinical Ophthalmology
Educational Director of Pediatric Ophthalmology/Subspecialty Division
President, Medical Staff UC San Diego Health System

Jolene Rudell, MD, PhD
Assistant Professor of Clinical Ophthalmology
PEDIATRIC OPHTHALMOLOGY & ADULT EYE REALIGNMENT
Strabismus/eye misalignment; double vision; amblyopia; retinopathy of prematurity; pediatric glaucoma and cataracts; including intraocular lens placement; nystagmus; congenital eye syndromes; craniofacial syndromes; systemic diseases affecting the eyes, nystagmus.

Peter J. Savino, MD
Professor of Ophthalmology & Neurosciences
NEURO-OPHTHALMOLOGY
Myasthenia gravis, optic neuritis; atrophy and neuropathy brain and nervous system; tumors; visual field defects, degenerative, metabolic, inflammatory and demyelinating diseases, vascular disorders.

Nathan L. Scott, MD, MPP
Assistant Professor of Clinical Ophthalmology
Division Chief, Ocular Oncology
OCULAR ONCOLOGY
Ocular oncology; uveal melanoma; retinoblastoma; choroidal hemangioma; ocular surface tumors (OSSN, conjunctival melanoma, lymphoma, etc.); ocular trauma; complicated retinal detachment; proliferative vitreoretinopathy; diabetic retinopathy; macular hole; age-related macular degeneration; retinal vascular occlusive disease; epiretinal membranes.

Peter Shaw, PhD
Associate Adjunct Professor of Ophthalmology
RETINA & VITREOUS
The impact of genetic and oxidative stress risk factors on ocular disease; development of molecular and gene therapy methods to treat eye diseases.

Doran B. Spencer, MD, PhD
Assistant Clinical Professor of Ophthalmology
UVEITIS
Uveitis and ocular inflammation.

Christopher B. Toomey, MD, PhD
Assistant Professor of Clinical Ophthalmology
RETINA & VITREOUS
Retina and vitreous; adult vitreoretinal disease, with specialization in age-related macular degeneration (AMD); diabetic retinopathy; retinal vein occlusions; retinal detachments; proliferative vitreoretinopathy; macular holes; and epiretinal membranes. Scientific interest in age-related macular degeneration with a focus on the early and intermediate “dry” stages of AMD.
GLAUCOMA
Glucoma management, clinical research in glaucoma and optic nerve assessment.

Cristiana Vasile, MD, MAS
Associate Clinical Professor of Ophthalmology

Karl Wahlin, PhD
Associate Professor of Ophthalmology
Director, Richard C. Atkinson Laboratory for Regenerative Ophthalmology

Derek S. Welsbie, MD, PhD
Associate Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Linda M. Zangwill, PhD
Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Derek S. Welsbie, MD, PhD
Associate Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Linda M. Zangwill, PhD
Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Linda M. Zangwill, PhD
Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Linda M. Zangwill, PhD
Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.

Linda M. Zangwill, PhD
Professor of Ophthalmology
GLAUCOMA
Neuroprotection in glaucoma and other optic neuropathies; use of functional genomic technologies to identify novel mediators of axon injury signaling in neurons; development of dual leucine zipper kinase inhibitors; role of dual leucine zipper kinase in traumatic brain injury.
The UC San Diego ophthalmology residency training is a three-year program with 12 resident physicians (four per year of training). Our highly selective residency program receives over 400 applications per year from throughout the country to fill four positions. The program is known for its outstanding clinical and surgical training, as well as the value placed on scholarships and compassionate patient care. Our residents are among the brightest and most motivated, and continue to be high achievers during and after their training. As a result, graduating residents are regularly chosen for competitive post-residency Fellowship training in various subspecialties of Ophthalmology, such as Cornea, Glaucoma, Ophthalmic Plastic and Reconstructive Surgery and Retina at the Shiley Eye Institute. Under the supervision of the renowned Shiley faculty, residents learn to care for patients, from common to very rare eye conditions. With departmental support, residents also participate in the many cutting-edge research opportunities available in the UC San Diego Viterbi Family Department of Ophthalmology and present their work at national meetings such as the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. The UC San Diego Ophthalmology Residency Training Program was recently recognized by the national accrediting body, the Accreditation Council for Graduate Medical Education, with a commendation on the excellence of the Residency Program and its faculty.

Residents

PGY-4 Residents
Justin Arnett, MD
Madi Eslani, MD
Jenny Hu, MD
Maya Yamanie, MD

PGY-3 Residents
Helena Gali, MD
Andrew Lin, MD
Rafaela Penteado, MD
George Villatoro, MD

PGY-2 Residents
Jimmy S. Chen, MD
Michael Saheb Kashaf, MD, MSc
Rebecca Lian, MD
Alexander Svoronos, MD, PhD

Fellows

Glaucoma
Tonking Bastola, PhD
Seunghawn Choi, PhD
“Gopika” Gopikasree Gunasegaran, MD
Alireza Kamalipour, MD, MPH
Kareem Latif, BS
Golnoush Mahmoudi Nezhad, MD, MPH
Takashi Nishida, MD, PhD
Kamran Rahmatnejad, MD
Catherine Sheils, MD
Daniel Wanderer, DVM
Jo-Hsuan (Sandy) Wu, MD

Glaucoma
Maria Paula Garcia, MD
Clemens Strohmaier, MD, PhD

Retina
Manisha Dagar, PhD
Daniel Deussen, MD, MSc
Carlo Garang, MD
Fritz Kalaw, MD
Zachary Koretz, MD
Delu Song, MD
Alexandra Warter, MD
Danae Woodard, PhD
Shaden Handy Fathy Yassin, PhD

Oculoplastics
Mahmoud Abouletta, MBChB
Eman Al-Sharif, MBBS
Nicole Topilow, MD

Cornea
Elina Jin, MD
Charity Lee, MD, MPH

Informatics
Byoungyoung Gu, MD
Kiana Tavakoli, MD

Pediatrics
Nicole Jody, MD
Maggie Santana, MD

NOT PICTURED
Maria Paula Garcia, MD
Clemens Strohmaier, MD, PhD

56
57
Graduation

GRADUATION OF RESIDENTS & FELLOWS

On June 15, 2023, the Viterbi Family Department of Ophthalmology and Shiley Eye Institute graduated outstanding residents and fellows with a virtual and in-person ceremony at the UC San Diego Moores Cancer Center Goldberg Auditorium.

Graduating Residents
Justin Arnett, MD (Administrative Chief Resident)
Medi Eslani, MD
Jenny Q. Hu, MD
Maya Yamane, MD (Academic Chief Resident)

Graduating Fellows
Man Li "Elina" Jin, MD (Cornea)
Charity Lee, MD, MPH (Cornea)
Alireza Kamalipour, MD, MPH (Glaucoma)
Takashi Nishida, MD, PhD (Glaucoma)
Kamran Rahmatnejad, MD (Glaucoma)
Catherine Sheils, MD (Glaucoma)
Nicole Topilow, MD (Oculoplastics)
Nicole Jody, MD (Pediatric Ophthalmology)
Carlo Galang, MD (Retina)
Etienne Schonbach, MD (Retina)
Delu Song, MD, PhD (Retina)

The tenth annual Lamont Ericson, MD Award for Outstanding Patient Care by a Resident was awarded to Maya Yamane, MD, by Residency Director Jeffrey Lee, MD. Dr. Ericson was an outstanding former resident in the department who passed away in 2007 at a young age. The department is grateful that Dr. Ericson’s family has supported his memory in this special way.

The Lanna Cheng Ophthalmology Innovation Award in recognition of outstanding Innovation in Research in Retina, was given to Christopher Toomey, MD, PhD.

The Lanna Cheng Ophthalmology Innovation Award in recognition of outstanding Innovation in Research in Ophthalmic Reconstructive and Oculofacial Plastic Surgery, was given to Catherine Liu, MD, PhD.

The Whitehill Teaching Award from the UC San Diego Health Sciences Academy of Clinical Scholars was given to Jiun Do, MD, PhD. The recipient is chosen by the Chief Residents and given to an Assistant or Associate level faculty member who best exemplifies compassionate bedside manner for learners to emulate, serves as an advocate for trainees, and encourages and facilitates clinical, translation or basic science research projects.

GRADUATION AWARDS

Award for Outstanding Clinical Teaching by a Resident
Justin Arnett, MD

Ophthalmic Knowledge Assessment Program (OKAP) Teaching Award
Peter Savino, MD

Outstanding Academic Achievement Award (OKAP)
Justin Arnett, MD

Outstanding Surgical Teaching
Weldon Haw, MD

Outstanding Clinical Teaching
Doran Spencer, MD, PhD

Award for Teaching by a Fellow
Delu Song, MD
Nicole Topilow, MD

Award for Outstanding Teaching
Scott McClatchey, MD

Education: Patients

2023 GLAUCOMA UPDATE

The fortieth annual Glaucoma Update was held in person and virtually on October 26, 2023 at the UC San Diego Moores Cancer Center Goldberg Auditorium. A hybrid meeting, this was the first in-person Glaucoma Update since 2020 and was simultaneously delivered by Zoom to attendees throughout the world.

Robert N. Weinreb, MD presented the latest trends in glaucoma treatments and research from the Shiley Eye Institute, Hamilton Glaucoma Center, and around the world. Additional presenters included faculty: Sally L. Baxter, MD, MSc, Alex A. Huang, MD, PhD, and Derek S. Welsbie, MD, PhD.
The Shiley Eye Institute and Viterbi Family Department of Ophthalmology in partnership with the Nixon Vision Foundation and Foundation Fighting Blindness held a free in-person seminar entitled “PRPH2 and Associated Retinal Disease Workshop” in late March 2023. Shyamanga Borooah, MBBS, PhD and Radha Ayyagari, PhD co-chaired the event with Claire Glefman, PhD, the Chief Science Officer of Foundation Fighting Blindness.

The goal of the workshop was to provide attendees with an understanding of the current landscape surrounding PRPH2- associated diseases, review the science and potential treatment approaches, as well as to identify key knowledge gaps to inform future funding in the field. The workshop was a combination of didactic sessions, patient perspectives, and discussion sessions. PRPH2-affected individuals and their families, researchers, physicians, and potential industry partners from around the world attended.
Education: Physicians

VISION RESEARCH LECTURES

The Vision Research Lecture Series addresses the latest advances in vision science and clinical ophthalmology. Each Presentation features UC San Diego Department of Ophthalmology’s faculty, as well as a selection of leading vision scientists from around the globe.

September 9, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Patricia Bocner, PhD
Senior Investigator
National Institutes of Health
Title: “PDFD Decreases the Susceptibility to Retinal Degeneration and Induces Senescence in the RPE”

October 6, 2022
Hosted by Saghigah, MD
Guest Lecturer: Arsham Sheybani, MD
Associate Professor of Ophthalmology and Visual Sciences
Washington University School of Medicine
Title: “UC San Diego and Washington U Joint Glaucoma Rounds”

November 10, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Michael V. Boland, MD, PhD
Associate Professor of Ophthalmology

Harvard Medical School
Site Director, Macu Eye and Ear, Lexington Medical Director, Practice Innovation for Ophthalmology of Massachusetts Eye and Ear
Title: “Advancing Academic Ophthalmology with Information Technology”

November 17, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Neelash Mandal, PhD
Associate Professor
Department of Ophthalmology
Department of Anatomy and Neurobiology
Hamilton Eye Institute
University of Tennessee Health Science Center
Title: “Sphingolipids in the Pathobiology of Eye Diseases and their Translational Relevance”

December 8, 2022
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Sheikh Amer Riazuddin, PhD, MS
Associate Professor of Ophthalmology
Wilmer Eye Institute, Johns Hopkins University School of Medicine
Title: “The promise of Molecular Genetics: Structures, Function, and Personalized Medicine”

December 13, 2022
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Alvin Liu, MD
Assistant Professor of Ophthalmology
Johns Hopkins University
Title: “Artificial Intelligence Initiatives at Johns Hopkins Medicine and the Wilmer Eye Institute”

January 12, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Lecturer: Lou Piquaule, MD
Professor of Ophthalmology
Mount Sinai Hospital and NYEE Eye and Vision Research Institute
Title: “Automating Clinical trial endpoints: Proof of principle in the idiopathic intracranial hypertension treatment trial”

January 19, 2023
Hosted by Radha Ayyagari, PhD
Guest Lecturer: Sudha K. yengar, PhD
Professor and Vice Chair for Research, Department of Population and Quantitative Health Sciences, Professor for the Department of Genetics and Genomics, and Professor for the Department of Ophthalmology and Visual Sciences
Case Western Reserve University School of Medicine
Title: “Surveying Eye Health in Diverse Populations Through the Electronic Health Record and Genetic Looking Glass”

January 25, 2023
Hosted by Juin Do, MD, MDN
Guest Lecturer: Benjamin Xu, MD, PhD
Assistant Professor of Ophthalmology and Director of Inpatient Ophthalmology Service
UCR Retina Eye Institute
Title: “UC San Diego and USC Joint Glaucoma Rounds”

February 9, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Durga Borkar, MD
Assistant Professor of Ophthalmology
Duke Eye Center/Duke University
Title: “Emerging Applications of Ophthalmology EHR Registries: the IRS Registry as a Case Study”

February 10, 2023
Hosted by Derek S. Walshe, MD, PhD
Guest Speaker: Kevin K. Park, PhD
Professor of Neurological Surgery and Director of Viral Vector Core at UH
University of Miami Miller School of Medicine
Title: “Mechanisms underlying Axonal Plasticity, Target Selection and Survival: Insights from Retinal Cells”

February 16, 2023
Hosted by Radha Ayyagari, PhD
Guest Speaker: Veronica Gomez Gudzine, PhD
Associate Project Scientist
University of California, San Diego
Title: “Cellular Biophotonics Toolbox”

March 9, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Jennifer K. Sun, MD, MPH
Associate Professor, Dept of Ophthalmology
Mayo Clinic
Title: “DRCR Retina Network Approach for Data Sharing and Management”

May 25, 2023
Hosted by Radha Ayyagari, PhD
Guest Speaker: Maayu R. Ali, PhD
Mayo Professor of Biomedical Engineering
University of Houston
Title: “Role of Flavins in Retinal Health and Disease”

Icahn School of Medicine at Mount Sinai
Title: “Neuroprotective and Regenerative Strategies for Vision Restoration”

April 13, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: J. Peter Campbell, MD, MPH
Associate Professor of Ophthalmology
Oregon Health & Science University
Title: “Imaging and Informatics in OIRP”

May 11, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Karen J. Sun, MD, MPH
Associate Professor of Ophthalmology
Massachusetts Eye and Ear Infirmary
Title: “DRCR Retina Network Approach for Data Sharing and Management”

May 25, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Jennifer K. Sun, MD, MPH
Associate Professor, Dept of Ophthalmology
Mayo Clinic
Title: “DRCR Retina Network Approach for Data Sharing and Management”

May 11, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: J. Peter Campbell, MD, MPH
Associate Professor of Ophthalmology
Oregon Health & Science University
Title: “Imaging and Informatics in OIRP”

May 25, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Maayu R. Ali, PhD
Mayo Professor of Biomedical Engineering
University of Houston
Title: “Role of Flavins in Retinal Health and Disease”

Icahn School of Medicine at Mount Sinai
Title: “Neuroprotective and Regenerative Strategies for Vision Restoration”

April 13, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: J. Peter Campbell, MD, MPH
Associate Professor of Ophthalmology
Oregon Health & Science University
Title: “Imaging and Informatics in OIRP”

May 11, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Karen J. Sun, MD, MPH
Associate Professor of Ophthalmology
Massachusetts Eye and Ear Infirmary
Title: “DRCR Retina Network Approach for Data Sharing and Management”

May 25, 2023
Hosted by Sally L. Baxter, MD, MSc
Guest Speaker: Maayu R. Ali, PhD
Mayo Professor of Biomedical Engineering
University of Houston
Title: “Role of Flavins in Retinal Health and Disease”

Icahn School of Medicine at Mount Sinai
Title: “Neuroprotective and Regenerative Strategies for Vision Restoration”
Summer Student Research Symposium

The Shiley Eye Institute and Viterbi Family Department of Ophthalmology sponsored a student symposium on August 28, 2023, to showcase the research from our National Eye Institute funded T35 summer student research program (STRIVE) and our senior medical students applying to ophthalmology residency. The student presentations were as follows:

Kaela Acuff
University of California San Diego (UCSD)
Senior Medical Student
Title: “Associations between Socioeconomic Factors and Visit Adherence among Patients with Glaucoma in the All of Us Research Program”
Faculty on Project: Robert N. Weinreb, MD and Sally L. Baxter, MD, MSc
Acuff analyzed the association between socioeconomic factors and visit adherence among patients with glaucoma in the All of Us Research Program, finding that lower education levels and lower income levels were associated with lower odds of seeing an eye care provider in the last 12 months. Notably, race was not significantly associated with visit adherence, as has been reported in prior studies. These findings highlight an important health disparity and may inform subsequent interventions to promote improved adherence to clinical guidelines regarding eye care for glaucoma monitoring and management.

Ivan Copado
University of California San Diego (UCSD)
Senior Medical Student
Title: “Disparities in Vision and Eye Care Utilization among Refugee and Migrant Populations in San Diego County”
Faculty on Project: Sally L. Baxter, MD, MSc
The research presented investigated the vision and eye care utilization patterns of refugee/migrant participants compared to control subjects in San Diego County. Copado established eligibility criteria using electronic health records (EHR) from UC San Diego Health Medical Centers. They examined a cohort of 64 refugee/migrant participants alongside 95 controls matched by country of origin, sex, and age. The results revealed significant differences, with refugee/migrant participants demonstrating higher enrollment in government-sponsored insurance programs, predominantly Medicaid, when compared to controls, fewer eye care encounters but increased ophthalmologist visits and procedures, underscoring the need for targeted interventions to enhance access to comprehensive eye care, potentially involving improved insurance coverage and collaboration with community organizations.

Leo Meller
University of California San Diego (UCSD)
UCSD Research Trainee
Title: “Association between Alcohol Use and Glaucoma using the National Institutes of Health All of Us Research Program”
Faculty on Project: Sally L. Baxter, MD, MSc
Meller utilized the National Institutes of Health All of Us Research Program to examine the association between alcohol use and glaucoma. His results indicated that alcohol use at least 2-3 times a week significantly increases the odds of glaucoma status. His research provides insight on another modifiable risk factor for glaucoma.

Andrew Tran
University of California San Diego (UCSD)
Senior Medical Student
Title: “Characterizing Retinal Fibrosis in a Novel Mouse Model of Ischemic Retinopathy”
Faculty on Project: Eric Nudelman, MD, PhD and Richard Daneman, PhD
Tran reported findings from his investigation of a novel mouse model of ischemic retinopathy, using imaging and functional studies in vivo. Employing fundus photography, optical coherence progression rate and laminar depth in the ADAGES cohort. Preliminary analysis of 13,600 Spectralis Optical Coherence Tomography optic nerve head images showed statistically significant relationships between faster visual field progression rates with deeper laminar depth, older age, and higher intraocular pressure. The study shows that lamina cribrosa change is independently associated with decreasing visual field performance, which links posterior remodeling of lamina cribrosa to progressive functional loss.

Karla Murillo
University of California Los Angeles (UCLA)
UCSD Research Trainee
Title: “Visual Field Progression Rate and Laminar Depth in the African Descent and Glaucoma Evaluation Study (ADAGES)”
Faculty on Project: Linda M. Zangwill, PhD and Nathan L. Scott, MD, MPP
Murillo’s objective was to determine the association between visual field progression rate and laminar depth in the ADAGES cohort. Preliminary analysis of 13,600 Spectralis Optical Coherence Tomography optic nerve head images showed statistically significant relationships between faster visual field progression rates with deeper laminar depth, older age, and higher intraocular pressure. The study shows that lamina cribrosa change is independently associated with decreasing visual field performance, which links posterior remodeling of lamina cribrosa to progressive functional loss.

Leo Meller
University of California San Diego (UCSD)
UCSD Research Trainee
Title: “Association between Alcohol Use and Glaucoma using the National Institutes of Health All of Us Research Program”
Faculty on Project: Sally L. Baxter, MD, MSc
Meller utilized the National Institutes of Health All of Us Research Program to examine the association between alcohol use and glaucoma. His results indicated that alcohol use at least 2-3 times a week significantly increases the odds of glaucoma status. His research provides insight on another modifiable risk factor for glaucoma.

Andrew Tran
University of California San Diego (UCSD)
Senior Medical Student
Title: “Characterizing Retinal Fibrosis in a Novel Mouse Model of Ischemic Retinopathy”
Faculty on Project: Eric Nudelman, MD, PhD and Richard Daneman, PhD
Tran reported findings from his investigation of a novel mouse model of ischemic retinopathy, using imaging and functional studies in vivo. Employing fundus photography, optical coherence progression rate and laminar depth in the ADAGES cohort. Preliminary analysis of 13,600 Spectralis Optical Coherence Tomography optic nerve head images showed statistically significant relationships between faster visual field progression rates with deeper laminar depth, older age, and higher intraocular pressure. The study shows that lamina cribrosa change is independently associated with decreasing visual field performance, which links posterior remodeling of lamina cribrosa to progressive functional loss.

Leo Meller
University of California San Diego (UCSD)
UCSD Research Trainee
Title: “Association between Alcohol Use and Glaucoma using the National Institutes of Health All of Us Research Program”
Faculty on Project: Sally L. Baxter, MD, MSc
Meller utilized the National Institutes of Health All of Us Research Program to examine the association between alcohol use and glaucoma. His results indicated that alcohol use at least 2-3 times a week significantly increases the odds of glaucoma status. His research provides insight on another modifiable risk factor for glaucoma.

Andrew Tran
University of California San Diego (UCSD)
Senior Medical Student
Title: “Characterizing Retinal Fibrosis in a Novel Mouse Model of Ischemic Retinopathy”
Faculty on Project: Eric Nudelman, MD, PhD and Richard Daneman, PhD
Tran reported findings from his investigation of a novel mouse model of ischemic retinopathy, using imaging and functional studies in vivo. Employing fundus photography, optical coherence progression rate and laminar depth in the ADAGES cohort. Preliminary analysis of 13,600 Spectralis Optical Coherence Tomography optic nerve head images showed statistically significant relationships between faster visual field progression rates with deeper laminar depth, older age, and higher intraocular pressure. The study shows that lamina cribrosa change is independently associated with decreasing visual field performance, which links posterior remodeling of lamina cribrosa to progressive functional loss.

Leo Meller
University of California San Diego (UCSD)
UCSD Research Trainee
Title: “Association between Alcohol Use and Glaucoma using the National Institutes of Health All of Us Research Program”
Faculty on Project: Sally L. Baxter, MD, MSc
Meller utilized the National Institutes of Health All of Us Research Program to examine the association between alcohol use and glaucoma. His results indicated that alcohol use at least 2-3 times a week significantly increases the odds of glaucoma status. His research provides insight on another modifiable risk factor for glaucoma.

Andrew Tran
University of California San Diego (UCSD)
Senior Medical Student
Title: “Characterizing Retinal Fibrosis in a Novel Mouse Model of Ischemic Retinopathy”
Faculty on Project: Eric Nudelman, MD, PhD and Richard Daneman, PhD
Tran reported findings from his investigation of a novel mouse model of ischemic retinopathy, using imaging and functional studies in vivo. Employing fundus photography, optical coherence progression rate and laminar depth in the ADAGES cohort. Preliminary analysis of 13,600 Spectralis Optical Coherence Tomography optic nerve head images showed statistically significant relationships between faster visual field progression rates with deeper laminar depth, older age, and higher intraocular pressure. The study shows that lamina cribrosa change is independently associated with decreasing visual field performance, which links posterior remodeling of lamina cribrosa to progressive functional loss.
tomography, and electroretinogram, he discovered mice exposed to the experimental condition exhibited retinal hemorrhage, persistent preretinal fibrotic plaque, retinal atrophy, and vision loss. This discovery indicates this mouse model’s usefulness in elucidating therapeutic targets and windows in the pathogenesis of fibrovascular change seen in diseases such as retinopathy of prematurity and diabetic retinopathy.

Core research team members include Malvika Arya, MD, PhD, Jimmy Chen MD, and John H.K. Liu, PhD.

Luke Valmadrid
University of California San Diego (UCSD)
UCSD Research Trainee
Title: "Auto Regulation as a Biomarker for Diabetic Retinopathy: Retinal Imaging in Different Postures"
Faculty on Project: Eric Nudleman, MD, PhD and John H.K. Liu, PhD
Mentored by Eric Nudleman, MD, PhD through the STRIVE program. Valmadrid is working on a pilot phase of retinal imaging in different postures using the handheld Remidio Fundus on Phone camera to characterize autoregulation as a biomarker for diabetic retinopathy and to assess the ability to evaluate retinal vessel autoregulation using standard clinical retinal pictures. Core research team members include Malvika Arya, MD, PhD, Jimmy Chen MD, and John H.K. Liu, PhD.

Jason Zhou
University of Maryland School of Medicine
UCSD Research Trainee
Title: "Use of EHR to Extract Normative Eyelid Measurements"
Faculty on Project: Don O. Kikkawa, MD, FACS
A retrospective single-institution EHR extraction was done on all adult patients seen by SEI’s Division of Oculoplastics. Zhou was primarily looking to identify and discriminate normative MRD1 measurements by age group, ethnicity, race, and sex, and secondarily comparing the data entry methods, Kaleidoscope, and progress notes. He found age group and race to be promising predictors of MRD and found a significant mean difference of 0.25mm between Kaleidoscope and progress notes.

The Viterbi Family Department of Ophthalmology and the Division of Preventive Medicine in the Department of Family Medicine at UC San Diego and the Graduate School of Public Health at San Diego State University (SDSU) have partnered to form the Global Ophthalmology and Advanced Leadership Program (GOAL).

Originally conceived by Vice Chair and Professor David B. Granet, MD, after completing his own graduate degree from the Harvard Chan School of Public Health, the Ophthalmology faculty quickly supported the idea. “We are proud to kick off this unique and innovative program that aligns with and extends the Shiley Eye Institute mission identifying, treating and preventing vision disorders,” said Robert N. Weinreb, MD.

The objective of the program is to train individuals to contribute as future leaders in global and preventive ophthalmology as well as impacting the systemic biases that affect equity in ophthalmic research and healthcare. After completing PGY1 (the internship part of residency), participants will enter a four-year program (PGY2 through PGYS), combining ophthalmology residency, preventive medicine residency, and course work for a Master’s Degree in Public Health (MPH). Upon completion of the program, graduates will be eligible for dual boards in Ophthalmology and Preventive medicine, as well as receive an MPH from SDSU.

They will have the knowledge and leadership skills to design and implement population based and public health-focused research and interventions, as well as broader ophthalmologic research that are applicable on a local and global scale. During the PGYS year, the program affords the opportunity to maintain clinical skills in ophthalmology as an attending physician and surgeon. Rebecca Lian, MD, who holds a Phi Beta Kappa undergraduate degree from UC Berkeley in Public Health, will be the first Resident to enter the program.
Christopher Toomey, MD, PhD, Assistant Professor of Ophthalmology, at the Shiley Eye Institute (SEI) and Viterbi Family Department of Ophthalmology has been awarded the Research to Prevent Blindness (RPB) Career Development Award. Toomey, a clinician-scientist, was nominated by Robert N. Weinreb, MD, Chair and Distinguished Professor, Viterbi Family Department of Ophthalmology. This award aims to support promising junior ophthalmology faculty who have demonstrated their potential for independent research.

Toomey expressed his appreciation saying, “The award is a great honor, “ and “Foundations like Research to Prevent Blindness address a big need for funding of the basic sciences. ”

The grant awarded to Toomey will support his ongoing research on age-related macular degeneration (AMD). It is a common condition and is a leading cause of vision loss for older adults. “About 20% of the population above the age of 70 has the disease,” said Toomey. Current AMD treatments are for patients who have vision loss and are in the late stages of their disease. The AMD research that Toomey is doing is focused on finding treatments to prevent the disease prior to the onset of vision loss. His goal is to treat people early on so they can be spared of all the complications associated with AMD. Toomey is a member of the Glycobiology Research and Training Center at UC San Diego. He works closely with Jeffrey Esko, PhD, Distinguished Professor, Department of Cellular and Molecular Medicine.

Toomey's research is focused on the role of glycans, “sugar-chains”, that cause extracellular aggregates of cellular debris and lipids in patients with AMD. Toomey says that, “once we characterize the binding dynamics between the debris and the glycans, we can develop therapeutics to cleanse the eye of these aggregates early in the disease process.” Notably, he was invited to present his research to Congress last year to emphasize the importance of preventative treatments.

Wonkyu “Daniel” Ju, PhD, Professor in the Viterbi Family Department of Ophthalmology, and the Shiley Eye Institute (SEI), was awarded $1,530,352 in UG3 grant funding by the National Institutes of Health (NIH) to support the development of novel gene therapy to reduce retinal neuroinflammation and provide effective neuroprotection to glaucoma patients.

Glaucoma remains a leading cause of global blindness by damaging the nerve in the back of the eye called the optic nerve. The symptoms start gradually so that they may not even be noticed. There is no cure for glaucoma, but early treatment can often stop the damage and protect sight. Therapies include eye drops, laser treatment or surgery. Emerging evidence suggests that glia-neuroinflammation is a critical element that leads to retinal ganglion cell (optic nerve cell) death and optic nerve degeneration in the development of glaucoma. According to Ju, “These studies will develop a novel gene therapy to reduce retinal neuroinflammation and mitochondrial dysfunction as well as provide effective neuroprotection to glaucoma patients.”

If successful, IND-enabling studies will be conducted at UC San Diego in order to obtain FDA approval for the first-in-human trial. Co-investigator Robert N. Weinreb, MD, Distinguished Professor and Chair of the Department of Ophthalmology, notes that “This prestigious grant is a groundbreaking moment as it’s the first time a glaucoma genetic therapeutic approach, spanning preclinical and clinical trials, has been awarded NIH funding.”

The project is a collaborative endeavor that draws upon the collective strengths and resources of UC San Diego, RAFT Pharmaceuticals, and the NIH Blueprint Neurotherapeutics Network – Biologic.

Christopher Toomey, MD, PhD
Assistant Professor of Ophthalmology
Uveitis

Wonkyu “Daniel” Ju, PhD
Professor
Glaucoma
William R. Freeman, MD, Distinguished Professor of Ophthalmology and Vice Chair, was awarded an R01 four-year research grant from the National Institutes of Health (NIH) to improve drug delivery directly into retinal cells.

As Director of the Irwin and Joan Jacobs Retina Center and Co-Director of the Retina Division, Freeman has been collaborating with Michael Sailor, PhD, Distinguished Professor of Chemistry and Biochemistry at UC San Diego, along with visiting scholar Joel Grondek, PhD. Freeman and Sailor have previously worked on ways to deliver drugs into the center of the eye using microparticles of porous oxidized silicon. The current grant takes this a step further by making particles even smaller (nano sized) and encapsulating drugs in these subcellular size sponges that cells absorb. This interaction alters the cellular metabolism to favorably affect a host of retinal diseases including diabetes and macular degeneration.

This new method of drug intake promises to be a long-acting therapy requiring less frequent injections to reduce new vessel growth and stop abnormal disease processes. By being able to place drugs in a nano sized drug carrier directly into retinal cells, the duration of action and efficacy of drugs for macular degeneration, diabetes and other retinal degenerations will be enhanced.

New NIH Grant

A porous silicon nanoparticle. The nanoparticle contains microscopic voids that can be loaded with drugs. The voids capture and then slowly release the drug, prolonging the beneficial effects of the drug.

Photo Credit: Gabriella Stark, UCSD

Note that the scale bar of 200 nanometers is 1/5 of a micron ie 1/5 of a thousandth of a millimeter. Or 1/100 the size of the width of a human hair.

Congratulations

DaNae R. Woodard, PhD

DaNae R. Woodard, PhD is a post-doctoral fellow and Institutional Research and Academic Career Development Awardee (IRACDA) (K12) at the Shiley Eye Institute (SEI) in the Radha Ayyagari, PhD laboratory. In her research project “Investigating the role of MFRP in early-onset retinal degeneration” she has recognized that knocking out the Mfpr gene in mice leads to early-onset abnormalities in photoreceptors and RPE. Her research focuses on deciphering the mechanisms that lead to MFRP-associated retinal degeneration and the function of MFRP.

Woodard was awarded a prestigious travel grant to the International Symposium on Retinal Degeneration (RD) 2023 meeting in Spain. Her presentation was titled “Integrative single-nucleus multi-omic analysis of retinal cell types involved in early-onset retinal degeneration due to the loss of MFRP.” This grant covered all travel related expenses and conference fees.

Anne Marie Berry

San Diego native Anne Marie Berry is a UC San Diego master’s student researcher in the laboratory of Radha Ayyagari, PhD at the Shiley Eye Institute (SEI). Berry is a part of the Contiguous BS/MS Program at UC San Diego, which allowed her to immediately go into her master’s program following her undergraduate degree.

Berry’s research is centered on employing single-cell genomics to investigate retinal degeneration, with a particular emphasis on aging. Berry was awarded an esteemed travel grant enabling her to attend and give a presentation at the International Symposium on Retinal Degeneration (RD) 2023 meeting in Spain.

Ann Marie Berry

DaNae R. Woodard, PhD

Anne Marie Berry
<table>
<thead>
<tr>
<th>Division</th>
<th>Faculty</th>
<th>Title</th>
<th>Project Period</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornea</td>
<td>Ahn, Natalie, MD</td>
<td>Whole Eye Sequencing for Variant Discovery in Fuchs Endothelial Corneal Dystrophy</td>
<td>11/01/2021-10/31/2023</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Baxter, Sally, MD, MSc</td>
<td>Multi-modal Health Information Technology Innovations for Precision management of Glaucoma</td>
<td>09/15/2020-08/31/2023</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Baxter, Sally, MD, MSc</td>
<td>Supplemental Graduate Student Support for Multi-modal Health Information Technology Innovations Project</td>
<td>09/01/2021-06/30/2022</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Baxter, Sally, MD, MSc</td>
<td>Short-term Research Training in Vision and Eye Health (STRT)</td>
<td>04/22/2023-03/27/2024</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Baxter, Sally, MD, MSc</td>
<td>OT2 Bridge to Artificial Intelligence (Bridge2AI) Program - Skills Development</td>
<td>09/01/2021-08/31/2022</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Christopher, Mark, PhD</td>
<td>Deep Learning Approaches to Detect Glaucoma and Predict Progression from Spectral-Domain Optical Coherence Tomography</td>
<td>08/01/2020-07/31/2022</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Du, Jin, MD, PhD</td>
<td>Development of Optic Nerve Relays to Restore Retinal Ganglion Cells</td>
<td>09/01/2021-08/31/2022</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Du, Jin, MD, PhD</td>
<td>Optic Nerve Relays for the Restoration of Visual Function</td>
<td>01/01/2021-03/31/2023</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Du, Jin, MD, PhD</td>
<td>Stem Cell-Derived Optic Nerve Relays to Restore Vision</td>
<td>03/01/2021-03/31/2024</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Huang, Alex, MD</td>
<td>Dynamic Variable Aquous Humor Outflow and Glaucoma Therapies in the Human Eye</td>
<td>05/01/2020-04/30/2025</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Huang, Alex, MD</td>
<td>Exercise Countermeasure to Prevent Ocular Structural and Functional Changes in a Terrestrial Model of SANS</td>
<td>08/22/2020-08/21/2021</td>
<td>NASA</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Huang, Alex, MD</td>
<td>I-SAFE (Investigating Structure and Function of the Eye)</td>
<td>08/20/2020-07/30/2023</td>
<td>NASA</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Huang, Alex, MD</td>
<td>Novel Ocular Imaging and Molecular Analysis of Anterior Eye Segments for Glaucoma</td>
<td>03/01/2023-02/28/2028</td>
<td>Northwestern University, NH/NIH as Prime</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Ju, Wonkyu, PhD</td>
<td>Mitochondrial Protection in Glaucomatous Optic Neuropathy</td>
<td>09/01/2020-06/30/2024</td>
<td>NH/NIH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Division</th>
<th>Faculty</th>
<th>Title</th>
<th>Project Period</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td>Ju, Wonkyu, PhD</td>
<td>Mitochondrial Protection in Glaucomatous Optic Neuropathy (Sub-awards)</td>
<td>09/01/2022-08/31/2023</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Ju, Wonkyu, PhD</td>
<td>AAV-ADP Therapy for Alzheimer's Disease</td>
<td>09/30/2022-05/31/2024</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Ju, Wonkyu, PhD</td>
<td>Neuroprotective Role of SRT in Glaucoma</td>
<td>06/20/2020-05/31/2023</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Ju, Wonkyu, PhD</td>
<td>CCR3-mediated Cell-cell Communication During Glaucoma</td>
<td>09/01/2022-07/31/2027</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Ju, Wonkyu, PhD</td>
<td>Reversing Microglial Inflammation and Mitochondrial Dysfunction in Alzheimer’s</td>
<td>09/01/2022-08/31/2027</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Mognini, Sanan, MD</td>
<td>Monitoring of Glaucoma Patients in Advanced Disease</td>
<td>09/01/2022-03/31/2027</td>
<td>NH/NIH R01</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Ophthalmology and Visual Sciences Career Development K12 Program</td>
<td>04/01/2021-07/31/2026</td>
<td>NIH K12</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Unrestricted and Challenge Grant - Research to Prevent Blindness</td>
<td>01/01/2023-12/31/2027</td>
<td>Research to Prevent Blindness</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography</td>
<td>05/01/2024-04/30/2025</td>
<td>NH/NIH R01</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>A Randomized, single Center, Masked, Crossover Study Comparing the Effects of Latanoprost and Timolol on Retinal Blood Vessel Density and Visual Acuity in Patients with Ocular Hypertension or Primary Open Angle Glaucoma</td>
<td>09/14/2018-08/31/2020</td>
<td>Baush &amp; Lomb</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>iGLAMOUR Study: Innovations in Glaucoma Adherence and Monitoring of Under-Represented Minorities</td>
<td>01/15/2021-12/31/2024</td>
<td>NH/NIHDOD R01</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Kinase Multitargeting for Glaucoma Neuroprotection</td>
<td>07/01/2018-06/30/2023</td>
<td>NH/NIH R01</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>High Throughput Functional Genomic Screening in Retinal Ganglion Cells</td>
<td>02/01/2019-01/31/2023</td>
<td>Glaucoma Research Foundation</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Developing an Optic Nerve Relay for Vision Restoration</td>
<td>01/01/2020-12/31/2022</td>
<td>Research to Prevent Blindness</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Development of Small Molecule and Gene Therapy Approaches to Inhibit Dual Leucine Zipper Kinase and Accessory Pathways for Retinal Ganglion Cell Neuroprotection</td>
<td>08/01/2020-07/31/2024</td>
<td>Perseus Biotherapeutics</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Weinreb, Robert, MD</td>
<td>Kinase Multitargeting for Glaucoma Neuroprotection</td>
<td>09/01/2022-03/30/2023</td>
<td>NIH/NEI</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Zangwill, Linda, PhD</td>
<td>OT2 Bridge to Artificial Intelligence (Bridge2AI) Program - Data Generation Multimodal Artificial Intelligence to Predict Glaucoma Progression and Surgical Intervention</td>
<td>09/01/2022-08/31/2027</td>
<td>NH/NIH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Division</th>
<th>Faculty</th>
<th>Title</th>
<th>Project Period</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornea</td>
<td>Afshari, Natalie, MD</td>
<td>Application of RNA-targeting Cas9 to Fuchs Endothelial Corneal Dystrophy</td>
<td>04/01/2018-05/31/2023</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Cornea</td>
<td>Afshari, Natalie, MD</td>
<td>Whole Eye Sequencing for Variant Discovery in Fuchs Endothelial Corneal Dystrophy</td>
<td>10/31/2021-10/31/2022</td>
<td>NH/NIH</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Novel Ocular Imaging and Molecular Analysis of Anterior Glaucoma</td>
<td>08/22/2022-08/21/2021</td>
<td>NASA</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Core Clinical management and Accelerate Clinical Trials</td>
<td>01/01/2023-12/31/2027</td>
<td>Research to Prevent Blindness</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>High-Throughput Functional Genomic Screening in Retinal Ganglion Cells</td>
<td>02/01/2019-01/31/2023</td>
<td>Glaucoma Research Foundation</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Development of Optic Nerve Relays to Restore Retinal Ganglion Cells</td>
<td>01/01/2020-12/31/2022</td>
<td>Research to Prevent Blindness</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Exercise Countermeasure to Prevent Ocular Structural and Functional Changes in a Terrestrial Model of SANS</td>
<td>08/22/2020-08/21/2021</td>
<td>NASA</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Development of Optic Nerve Relays to Restore Retinal Ganglion Cells</td>
<td>01/01/2021-03/31/2023</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Stem Cell-Derived Optic Nerve Relays to Restore Vision</td>
<td>03/01/2021-03/31/2024</td>
<td>America Glaucoma Foundation</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Dynamic Variable Aquous Humor Outflow and Glaucoma Therapies in the Human Eye</td>
<td>05/01/2020-04/30/2025</td>
<td>NH/NEI</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Exercise Countermeasure to Prevent Ocular Structural and Functional Changes in a Terrestrial Model of SANS</td>
<td>11/01/2021-09/30/2023</td>
<td>Perceiv Foundation</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>I-SAFE (Investigating Structure and Function of the Eye)</td>
<td>08/20/2020-07/30/2023</td>
<td>NASA</td>
</tr>
<tr>
<td>Cornea</td>
<td>Huang, Alex, MD</td>
<td>Novel Ocular Imaging and Molecular Analysis of Anterior Eye Segment for Glaucoma</td>
<td>03/01/2023-02/29/2028</td>
<td>Northwestern University, NH/NIH as Prime</td>
</tr>
<tr>
<td>Cornea</td>
<td>Ju, Wonkyu, PhD</td>
<td>Mitochondrial Protection in Glaucomatous Optic Neuropathy</td>
<td>09/01/2020-06/30/2024</td>
<td>NH/NIH</td>
</tr>
</tbody>
</table>
Diagnosis Innovations in Glaucoma Study (DIGS): High Myopia and Advanced Diseases
07/01/2022-06/30/2026 NIH/NEI

Translational Vision Research Training at UCSD
04/01/2016-06/20/2026 NIH/NEI

Personalized Forecasting of Disease Trajectory for Patients with Open Angle Glaucoma
09/30/2015-05/31/2020 NIH/NEI

Retina Ayyagari, Radha, PhD Expert Curation of Clinically Significant Variants in Genes Responsible for Macular Degenerations
09/01/2021-08/31/2027 NIH/NEI

Translational Vision Research Training at UCSF
06/01/2023-05/31/2024 NIH/NEI K08

Pediatrics Rudell, Jolene, MD, PhD Role of Fibroblast Growth Factor Signaling in a Genetic Model of Strabismus
12/01/2022-11/30/2024 UCSD/ACTRI

Pediatrics Rudell, Jolene, MD, PhD Role of Rho GTPase Signaling in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 UCSF/ACTRI

Pediatrics Rudell, Jolene, MD, PhD Role of Basigin in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NEI/NIH

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen II in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen III in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen IV in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen V in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen VI in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen VII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen VIII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen IX in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen X in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XI in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XIII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XIV in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XV in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XVI in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XVII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XVIII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XIX in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XX in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXI in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXIII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXIV in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXV in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXVI in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXVII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXVIII in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXIX in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI

Pediatrics Rudell, Jolene, MD, PhD Role of Collagen XXX in Extracellular Matrix Remodeling
12/01/2022-11/30/2024 NIH/NEI
Clinical Trials 2023

<table>
<thead>
<tr>
<th>Division</th>
<th>Principal Investigator</th>
<th>Title</th>
<th>Project Period</th>
<th>Funding Agency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornea</td>
<td>Ajman, Natalie, MD</td>
<td>Phase 1 Safety Run-in and Phase 2 Randomized Clinical Trial of Atenumab-Ranibizumab and NV-3475 (Pembrolizumab) Compared to NV-3475 (Pembrolizumab) alone for Macular Polypoidal Neovascularization</td>
<td>07/09/2019-03/01/2023</td>
<td>National Cancer Institute (NCI)</td>
</tr>
<tr>
<td>Cornea</td>
<td>Hochel, Christopher, MD</td>
<td>A Thirteen-year Study of the Indications and Visual Outcomes of Capsular Tension Ring Implantation in Cataract Surgery 2016</td>
<td>07/01/2016-06/30/2020</td>
<td>ReGen Tree</td>
</tr>
<tr>
<td>Cornea</td>
<td>Haw, Weldon, MD</td>
<td>A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Fluraxol-Fluraxol-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RN295 295 Photophiles Solution for the Treatment of Tuniclear Keratopathy (SUER-JP)</td>
<td>2023</td>
<td></td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Camp, Andrew, MD</td>
<td>The Efficacy and Safety of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension</td>
<td>04/01/2020-03/31/2023</td>
<td>Alcon Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Camp, Andrew, MD</td>
<td>An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular Hypertension</td>
<td>09/06/2017-03/15/2024</td>
<td>Allergan</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Wan, Robert, MD</td>
<td>Evaluate Clinical Big Data Provided by TOPOCON and Derived from Ocular Hypertension</td>
<td>07/01/2022-06/30/2026</td>
<td>TOPCON</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Zangwill, Linda, PhD</td>
<td>Multi-center Study for a Reference Database of Optic Nerve Head: Retinal Nerve Fiber Layer, and Macula Parameters Measured with the Heidelberg Spectralis OCT within a Hispanic Population</td>
<td>02/16/2018-01/31/2023</td>
<td>Heidelberg Engineering</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Zangwill, Linda, PhD</td>
<td>Multi-center Study for a Reference Database of Optic Nerve Head: Retinal Nerve Fiber Layer, and Macula Parameters Measured with the Heidelberg Spectralis OCT within a Hispanic-American Population</td>
<td>02/27/2018-01/31/2023</td>
<td>Heidelberg Engineering</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Zangwill, Linda, PhD</td>
<td>Grading the Ocular Images and Datasets for the B-2018-4 Study</td>
<td>06/15/2019-06/14/2023</td>
<td>Heidelberg Engineering</td>
</tr>
<tr>
<td>Oculoplastics</td>
<td>Liu, Catherine, MD, PhD</td>
<td>A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPPEA in Treating Patients with Chronic Inactive Thyroid Eye Disease</td>
<td>03/23/2021-02/22/2021</td>
<td>Horizon Therapeutics USA, Inc.</td>
</tr>
<tr>
<td>Oculoplastics</td>
<td>Liu, Catherine, MD, PhD</td>
<td>A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Rebrilin Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration (KSI301)</td>
<td>02/14/2019-09/20/2024</td>
<td>Genentech, Inc.</td>
</tr>
</tbody>
</table>

Division | Principal Investigator | Title | Project Period | Funding Agency |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatrics</td>
<td>Robbins, Shira, MD</td>
<td>A Multi-center, Double-masked, Placebo-controlled Phase 3 Study of the Safety and Efficacy of Droz0.1% and 0.01% (Ilotiapril) Solutions Administered with a Microdose Impression for the Reduction of Pediatric Myopia Progression</td>
<td>04/01/2020-12/31/2023</td>
<td>Eyenovia, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>Natural History Study of Patients with E-linked Retinal Dysplasia Associated with Mutations in Retinitis Pigmentosa GT1Pase (RPG)</td>
<td>03/05/2021-09/20/2025</td>
<td>Meiragtx UK II Limited</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>Phosphotony and Genotyping Patients with Achromatopsia in Preparation for Therapy Trials</td>
<td>03/03/2021-03/02/2023</td>
<td>Meiragtx UK II Limited</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>A Phase 2 Randomized Placebo-controlled double-masked Study to Assess Safety &amp; Efficacy of Multiple Doses of ENX-78-1-X in An inherited Retinal Dystrophy</td>
<td>12/17/2019-12/31/2022</td>
<td>Ions Pharmaceuticals, Ltd.</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>A Phase 3 Randomized Controlled Study of AAV-HNHP-RPG for the Treatment of Stargardt's and Pigmentary Detachment Associated with Variants in the PRG5 Gene</td>
<td>07/30/2020-07/29/2021</td>
<td>Meiragtx UK II Limited</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>Phase 3 Follow-up Study of AAV6-HNHP-RPG for the Treatment of Stargardt's and Pigmentary Detachment Associated with Variants in the PRG5 Gene</td>
<td>08/10/2021-08/09/2021</td>
<td>Meiragtx UK II Limited</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>A Phase 1/2 Study To Assess the Safety and Efficacy of Oculin for Retinitis Pigmentosa Associated with S39C or R8 Mutations</td>
<td>10/18/2022-10/18/2023</td>
<td>Ocugen, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>A Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate the Safety and Tolerability of QR-421a in Participants with Geographic Atrophy Associated with Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)</td>
<td>06/06/2022-07/07/2023</td>
<td>PROQR THERAPEUTICS IV B.V.</td>
</tr>
<tr>
<td>Retina</td>
<td>Boroosh, Shyamanga, MD, PhD</td>
<td>GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of ENX-78-1-X in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)</td>
<td>11/2020-07/2023</td>
<td>Ions Pharmaceuticals, Ltd.</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of the Port Delivery System with Adenovirus AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR Gene</td>
<td>01/21/2021-01/20/2026</td>
<td>Medisca, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Phase 1 Safety Study of Retina Freeman, William, MD A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Rebrilin Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration (KSI301)</td>
<td>02/10/2020-12/31/2022</td>
<td>Kodiak Sciences, Inc.</td>
</tr>
<tr>
<td>Division</td>
<td>Principal Investigator</td>
<td>Title</td>
<td>Project Period</td>
<td>Funding Agency</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------</td>
<td>-------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Phase 3 Multicenter, Randomized, Double-masked, Sham-controlled Clinical Trial to assess the Safety and Efficacy of Intravitreal Administration of ZMURAT™ (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GATHER2)</td>
<td>06/18/2020-12/31/2023</td>
<td>IVERIC Biosciences</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Randomized, Double-masked, Phase 3 Study of ABF 958 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration</td>
<td>08/10/2020-12/31/2023</td>
<td>AMGEN Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Phase 2, Double-masked, Placebo-controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)</td>
<td>03/19/2021-06/30/2022</td>
<td>Kodiak Sciences, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Aflibercept in Patients with Neovascular Age-related Macular Degeneration (AMD)</td>
<td>04/02/2021-06/30/2022</td>
<td>Kodiak Sciences, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>A Phase 3, Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Efficacy of PEGECAPOLAN in subjects with Geographic Atrophy 2nd to AMD (GALE)</td>
<td>07/01/2021-12/31/2023</td>
<td>Apellis Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>An Open-label Extension Phase 3 Trial to Assess the Safety of Intravitreal Administration of Acrastin Pegol (complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study (1E2E008)</td>
<td>04/26/2023-12/31/2023</td>
<td>IVERIC Biosciences</td>
</tr>
<tr>
<td>Retina</td>
<td>Freeman, William, MD</td>
<td>An Open-label Extension Phase 3 Trial to Assess the Safety of Intravitreal Administration of Acrastin Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study (1E2E008)</td>
<td>07/28/2023-12/31/2026</td>
<td>Janssen Research &amp; Development LLC</td>
</tr>
<tr>
<td>Retina</td>
<td>Nuudelman, Eric, MD, PhD</td>
<td>A 2-year, 3-center, Randomized, Double-masked, Multicenter, Phase II Study Assessing the Efficacy and Safety of Brexucabtagan vs Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KIERLE)</td>
<td>11/01/2018-06/30/2023</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Nuudelman, Eric, MD, PhD</td>
<td>A Randomized, Controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity (ROP)</td>
<td>05/06/2020-12/31/2022</td>
<td>Regeneron Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Nuudelman, Eric, MD, PhD</td>
<td>An Extension Study to Evaluate the Long-term Outcomes of Patients who Received Treatment for Retinopathy of Prematurity in the VGFTE-ROP-1922 Study</td>
<td>04/20/2021-12/31/2026</td>
<td>Regeneron Pharmaceuticals</td>
</tr>
<tr>
<td>Retina</td>
<td>Nuudelman, Eric, MD, PhD</td>
<td>Testing Collagen Probes and Bioprosthetic VEGF/Ang-2 Suppression</td>
<td>04/01/2022-04/30/2025</td>
<td>F. Hoffman-La Roche Ltd</td>
</tr>
<tr>
<td>Retina</td>
<td>Nuudelman, Eric, MD, PhD</td>
<td>A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RXR-314 Gene Therapy in Participants with AMD</td>
<td>05/10/2022-12/31/2026</td>
<td>Regendio Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Spencer, Donor, MD, PhD</td>
<td>A Phase III, Multicenter, Randomized, Double-masked, Active Comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-related Macular Degeneration (TENAX)</td>
<td>06/07/2019-06/30/2023</td>
<td>Genentech, Inc.</td>
</tr>
<tr>
<td>Retina</td>
<td>Spencer, Donor, MD, PhD</td>
<td>A Phase 3 Randomized, Active-controlled, Double-masked Study to Evaluate the Safety and Efficacy of TRI-350 Eye Drops in the Treatment of Subjects with Active Non-infectious Anterior Uveitis including Subjects with Uveitic Glaucma</td>
<td>12/02/2022-11/30/2024</td>
<td>Trianer Pharma</td>
</tr>
</tbody>
</table>
Giving Opportunities

For 33 years, the philanthropic support from generous individuals, foundations and corporations has provided the Shiley Eye Institute (SEI) and the Viterbi Family Department of Ophthalmology with valuable resources for patient care, research, education and community service. As a friend of the Department of Ophthalmology, there are several giving options for those who wish to contribute to our tradition of excellence.

Outright Gifts – Immediate Impact

Your support in the form of cash, check, credit cards, stocks, marketable securities, wires or property provides immediate impact to our faculty and facility at SEI. If writing a check, please make payable to the Shiley Eye Institute in the memo section.

Annual Gifts – Circle of Sight

Established in 1996, the Circle of Sight is the Shiley Eye Institute’s program recognizing donors contributing $520 or more annually to support the Department’s crucial needs. Members enjoy exclusive events like Vision Research Lectures, receptions, and opportunities to connect with faculty. Serving as ambassadors in the San Diego community, Circle of Sight members play a vital role in driving our successful initiatives.

Planned/Estate Gifts – Your Vision for Tomorrow

Please consider a charitable bequest in your estate plan to contribute to the future of the Shiley Eye Institute and provide direct support to the Viterbi Family Department of Ophthalmology. We are happy to assist you, your attorney, accountant, or tax advisor with the specific bequest language for your will, trust, or retirement account beneficiary designation. This can help reduce the tax impact on your heirs or provide assurance that your assets will benefit those you care about.

Tribute Gifts – Acknowledge Someone Special

Contributions can be made in memory, honor or in celebration of a loved one or to mark a special occasion. Consider honoring a particular physician who played a significant role in your eye health. This thoughtful gift not only creates a lasting legacy but also directly supports the Department.

Matching Gifts – Double your Gift

Your donations can have an even greater impact as many employers have a matching gift program. Simply obtain a Matching Gift Form from your employer.

Endowments – Gifts in Perpetuity

A gift of endowment shows your lasting dedication to the Department of Ophthalmology, as the fund is maintained in perpetuity. This contribution can fund programs, lectures, awards, fellowships, and Chairs. Endowments can be created in memory, honor or in carrying the name of the donor or a loved one.

Gifts of Real Estate

Donating real estate is a generous and financial benefit way to support the Shiley Eye Institute. If you have residential rental units, vacation homes, or other properties that no longer meet your needs, they can be used to support Shiley’s programs. Whether it’s an outright gift, bargain sale, retained life estate, charitable gift annuity, or charitable remainder trust, real estate offers creative ways to unlock financial security and provide immediate tax benefits while supporting the programs that matter to you at the Shiley Eye Institute.

Annual Gifts

The check should be accompanied with a writing a check, please make payable to Shiley Eye Institute in the memo section.

Matching Gifts

Double your Gift

Your donations can have an even greater impact as many employers have a matching gift program. Simply obtain a Matching Gift Form from your employer.

Endowments

Gifts in Perpetuity

A gift of endowment shows your lasting dedication to the Department of Ophthalmology, as the fund is maintained in perpetuity. This contribution can fund programs, lectures, awards, fellowships, and Chairs. Endowments can be created in memory, honor or in carrying the name of the donor or a loved one.

Gifts of Real Estate

Donating real estate is a generous and financial benefit way to support the Shiley Eye Institute. If you have residential rental units, vacation homes, or other properties that no longer meet your needs, they can be used to support Shiley’s programs. Whether it’s an outright gift, bargain sale, retained life estate, charitable gift annuity, or charitable remainder trust, real estate offers creative ways to unlock financial security and provide immediate tax benefits while supporting the programs that matter to you at the Shiley Eye Institute.

For further information about donating, please contact:
Karen Anisko Ryan
Phone: 858-534-8017
Email: kanisko@health.ucsd.edu

Donor Advised Fund (DAF): Contribute to a DAF and enjoy a tax savings when you donate. You can then recommend a grant (or recurring grant) to the Shiley Eye Institute and enjoy a tax deduction.

Qualified Charitable Distributions (QCD): Whether or not you itemize, if you are at least 70½, you can make a QCD from your IRA to support the Shiley Eye Institute. A QCD is not includable in your reportable taxable income, and if you take required minimum distributions, a QCD will count toward some or all of that amount. Note that the QCD limit is $100,000, so it’s a good way to manage your financial situation next year, including your annual Medicare contributions.

Charitable Gift Annuity (CGA): If you are looking to increase your financial security in retirement, consider creating a CGA to provide a guaranteed lifetime income stream and immediate tax benefits. CGA annuity rates are at their highest level in years and now you can make a one-time transfer of up to $53,000 (in 2024) from an IRA to a CGA (with certain restrictions).

Donor Advised Fund (DAF): Contribute to a DAF and enjoy a tax savings when you donate. You can then recommend a grant (or recurring grant) to the Shiley Eye Institute and enjoy a tax deduction.

Qualified Charitable Distributions (QCD): Whether or not you itemize, if you are at least 70½, you can make a QCD from your IRA to support the Shiley Eye Institute. A QCD is not includable in your reportable taxable income, and if you take required minimum distributions, a QCD will count toward some or all of that amount. Note that the QCD limit is $100,000, so it’s a good way to manage your financial situation next year, including your annual Medicare contributions.

Charitable Gift Annuity (CGA): If you are looking to increase your financial security in retirement, consider creating a CGA to provide a guaranteed lifetime income stream and immediate tax benefits. CGA annuity rates are at their highest level in years and now you can make a one-time transfer of up to $53,000 (in 2024) from an IRA to a CGA (with certain restrictions).

Donor Advised Fund (DAF): Contribute to a DAF and enjoy a tax savings when you donate. You can then recommend a grant (or recurring grant) to the Shiley Eye Institute and enjoy a tax deduction.

Qualified Charitable Distributions (QCD): Whether or not you itemize, if you are at least 70½, you can make a QCD from your IRA to support the Shiley Eye Institute. A QCD is not includable in your reportable taxable income, and if you take required minimum distributions, a QCD will count toward some or all of that amount. Note that the QCD limit is $100,000, so it’s a good way to manage your financial situation next year, including your annual Medicare contributions.

Charitable Gift Annuity (CGA): If you are looking to increase your financial security in retirement, consider creating a CGA to provide a guaranteed lifetime income stream and immediate tax benefits. CGA annuity rates are at their highest level in years and now you can make a one-time transfer of up to $53,000 (in 2024) from an IRA to a CGA (with certain restrictions).

Donor Advised Fund (DAF): Contribute to a DAF and enjoy a tax savings when you donate. You can then recommend a grant (or recurring grant) to the Shiley Eye Institute and enjoy a tax deduction.

Qualified Charitable Distributions (QCD): Whether or not you itemize, if you are at least 70½, you can make a QCD from your IRA to support the Shiley Eye Institute. A QCD is not includable in your reportable taxable income, and if you take required minimum distributions, a QCD will count toward some or all of that amount. Note that the QCD limit is $100,000, so it’s a good way to manage your financial situation next year, including your annual Medicare contributions.

Charitable Gift Annuity (CGA): If you are looking to increase your financial security in retirement, consider creating a CGA to provide a guaranteed lifetime income stream and immediate tax benefits. CGA annuity rates are at their highest level in years and now you can make a one-time transfer of up to $53,000 (in 2024) from an IRA to a CGA (with certain restrictions).

Donor Advised Fund (DAF): Contribute to a DAF and enjoy a tax savings when you donate. You can then recommend a grant (or recurring grant) to the Shiley Eye Institute and enjoy a tax deduction.

Qualified Charitable Distributions (QCD): Whether or not you itemize, if you are at least 70½, you can make a QCD from your IRA to support the Shiley Eye Institute. A QCD is not includable in your reportable taxable income, and if you take required minimum distributions, a QCD will count toward some or all of that amount. Note that the QCD limit is $100,000, so it’s a good way to manage your financial situation next year, including your annual Medicare contributions.
Your Gifts Create Positive Impact

In April 2023, Robert N. Weinreb, MD, received an inquiry from a longtime patient who read an article in our 2022 annual report about the funding need for a new EyeMobile. After learning more about the new project, Bruce and Janet Lawrence generously made a gift to retrofit the older EyeMobile for Children to accommodate seniors as well as fund the first year of service.

*In various conversations over the past couple years, I have been made aware of Dr. Weinreb’s desire to have a mobile eye clinic for underserved seniors in addition to the current clinic for children,* noted Bruce. *We are very impressed with the scope of this project."

The new Shiley EyeMobile is in the process of being retrofitted and should be on the road in early 2024.

*"We are so grateful to the Lawrences for this transformative gift bringing eye care to the underserved seniors of San Diego County," stated Weinreb.

Making a Difference!

The Martha Proctor Mack Foundation kindly donated a groundbreaking new piece of technology, the OcuMet Beacon, to the Shiley Eye Institute and Viterbi Family Department of Ophthalmology that provides critical information on mitochondria (the energy producing organelles of cells) to better diagnose and treat patients with age related macular degeneration (AMD) earlier than other imaging devices. It produces a rapid non-invasive light beam that provides a specialized image of the retina. The image is then analyzed to detect the presence of AMD earlier. It is also able to determine in patients with existing AMD - whether it is worsening. Appropriate treatment to optimize the healthiest vision possible then can then be administered.

Assistant Professor Nathan Scott, MD, MPP will be primarily utilizing the piece of equipment looking at retinas as well as examining patients for cancerous tumors.
Gifts of $100,000 and Above
Marilyn and David Anderson
Hanna N. and Mark Gleberson
Bruce L. Deck
Sally A. McMurray Fund
Nixon Visions Foundation
Darlene V. Shiley

Gifts of $100,000 to $49,999
Rudi Urlau
Jeanna Shiley
The Wilson Sexton Foundation
Buzz and Peg Gitelson
Farrell Family Foundation

Gifts of $25,000 to $49,999
American Glaucoma Society
Anonymous (1)
Jane T. and Thompson Fetter
Wayne Green
Mark Voss-Overman

Gifts of $5,000 to $9,999
American Foundation for the Blind

Gifts of $500 to $999
American Glaucoma Society
Anonymous
(1)
Sari Simchoni and Al Blum
Price Philanthropies Foundation
Wayne Green
Jane T. and Thompson Fetter
Anonymous (1)
American Glaucoma Society
The Foundation Fighting Blindness
Rustin and Daneesh Appoo

Gifts of $25,000 to $49,999
Farrell Family Foundation
Buzg and Peg Gitelson
Heidelberg Engineering, Inc
Scipior Howard Foundation
The Wilson Sexton Foundation
Jeanna Shiley
Patricia Shiley
Rudi Urlau

Gifts of $5,000 to $9,999
Rustin and Daneesh Appoo

Gifts of $500 to $999
Anonymous
(4)
Khoa Ong
Michael G. Qualls
Mary and Herb Rabe

Gifts of $250 to $499
Georges Anagnostopoulos
Anonymous

Gifts of $50 to $999
Diane Amatangelo
Anonymous

Gifts of $250 to $499
Diane Amatangelo
Anonymous

Gifts of $50 to $999
The Diane and Elliot Feuerstein Fund of the Jewish Community Foundation
Lipton and Mary L. Weinberg
Sue Cooke
Gerald H. Sova / Captain Keno's Restaurant

Gifts of $500 to $999
Khoa Ong
Michael G. Qualls
Mary and Herb Rabe

Gifts of $100 to $249
Anonymous
(7)
Claudia Libenson

Gifts of $50 to $999
Anonymous
(7)
Claudia Libenson
Claudia Lowenstein
Christine M. Lux-Whiting
Mahnood F. Maahdeh, MD
Martha C. Mann
Richard C. Manfield
Larry Manzner
Diane Martin
Robert W. McClamara
Cora R. Monge
Brian K. and Luisa D. Monson
Joe Muria
Julee Nelson
Mr. and Mrs. Timothy Neufeld
Althoy Nguyen T.
Mary Nguyen
Toni Nickell
Mr. and Mrs. Philip Nordhues
Dr. and Mrs. Nairin A. Owsia
Noel Parker
Robert K. Poon
James and Janet Respess
Danina E. Robinson
Tom K. Roesbeck
Thomas J. Roycaft
Georgia and Bari Sadler
LCDR John R. Savory, USN (Ret.)
Lisa Shih
Dr. and Mrs. Seymour Silverberg
Anne and Ronald Simon
Martha S. Sloan
Elaine Soliven
Maria Swain, PhD
Mr. and Mrs. Ronald L. Tabor
Rerenew Jesse A. and Dorothy L. Tate
Jane Turfo
John and Judy Turner
Suzie M. Vidish
Andrew J. Viterbi, PhD in memory of Suzanne Angeli
Janice T. Webb
Bing Yuan Wei
Timothy L. White
Todd and Chem Wilkinson
Susie Wolff
Lui Ye
Mr. and Mrs. Robert S. Yuan

Gifts up to $99
Anonymous (5)
Lorna K. Balliff
William J. Bartley
Delamae L. Bartolome
Emerilda C. Bandalian
Yinna Chau
Ivonne Choy-Martinez
Judith A. Corcancion
Guillermina and Mariela Cornejo
Yolanda D. Cruz
Mr. Hoang J. Dang
Jerry and RoseAnn DelCastillo
Penny Duermeyer
Mrs. Leslie A. Evans
Margarita Garcia
Rita Geller
Jan Glenn
Annamaria and June Green
Bo Sheng Gu
Milton Hukeman
Pia Harris-Ebert
Jane S. Hiers
John Husbiner
Shen S. Huang
Oleg Izhuvanzov
Janice and Donald LeMay
Ann Lerner
Amelia D. Lindlar
Juanito and Carmelita Mariano
Michael Knobler
Deborah McCormac
Ghansam - Gay Michael
Anna Minewa
Mrs. and Mr. S. W. Moore
Wendy M. Morgan
Sam M. Naghavian
Mary C. Neis
Ms. Kathryn Newmark and Mr. Matthew Costello
Elena Oliva
Rhibiton M. Panthaky Family
Linda Peterson
Gary Phaneuf
Jesliada Pilam

MEMORIALS

The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute at UC San Diego sadly acknowledges friends and key supporters who have passed away during the past year. They remain in our thoughts.

Dr. Albert John Fredman
Martin J. Gannon
Dr. Harold R. Hall
Dr. Dimitrios T. Liaris
Hyunshul Kim
Dr. Thomas Roy Mack

Charlie McGarr
Frances P. Osborn
Dr. Gene W. Ray
Wilton Sexton
Dr. Howard W. Weiner
Irwin Zahn